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Abstract
In this dissertation we propose methodology for testing SNP-sets for genetic associ-
ations, both for sequencing and genome-wide association studies. Due to the large scale
of this kind of data, there is an emphasis on producing methodology that is not only
accurate and powerful, but also computationally efficient.
In the Chapter 1, we aim at using extreme phenotype sampling to increase the power
to identify rare variants associated with complex traits. We confirm both analytically and
numerically that sampling individuals with extreme phenotypes can enrich the presence
of causal rare variants and can therefore lead to an increase in power compared to random
sampling. While application of traditional rare variant association tests to these extreme
phenotype samples requires dichotomizing the continuous phenotypes before analysis,
the dichotomization procedure can decrease the power by reducing the information in
the phenotypes. To avoid this, we propose a novel statistical method based on optimal
SKAT (SKAT-O) that allows us to test for rare variant effects using continuous phenotypes
in the analysis of extreme phenotype samples. The increase in power of this method is
demonstrated through simulation of a wide range of scenarios as well as in the triglyc-
eride data of the Dallas Heart Study.
In Chapter 2, we present the higher criticism, a signal detection method that is effec-
tive for testing the joint null hypothesis against a sparse alternative, in the context of
SNP-set testing. This test is useful for testing the effect of a gene or a genetic pathway
that consists of d genetic markers. Accurate p-value calculations for the higher criticism
based on the asymptotic distribution require a very large d, which is not the case for the
number of genetic variants in a gene or a pathway. We propose an analytic method that
iii
accurately computes the p-value of the higher criticism test for finite d problems. Unlike
previous treatments of the higher criticism, this method does not rely on asymptotics in
d or simulation, and is exact for arbitrary d when test statistics are normally distributed.
The method is also particularly computationally advantageous when d is not large. We il-
lustrate the proposed method with a case-control genome-wide association study of lung
cancer and compare its power to competing methods through simulations.
In Chapter 3, we adapt the higher criticism to better allow for correlation in the SNP-
set. In Chapter 2, the SNPs in the SNP-set are first decorrelated, which loses power. We
propose the generalized higher criticism (GHC) that does not require asymptotics in the
number of SNPs in the SNP-set while simultaneously allowing for arbitrary correlation
structures among the SNPs in the SNP-set. The detection boundary of the test is obtained,
and the power of this method is compared with existing SNP-set tests over simulated
regions with varied correlation structures and signal sparsity. The relative performance
of these methods is also compared in their analysis of the CGEM breast cancer genome-
wide association study.
iv
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1.1 Introduction
With the increase in the number of sequencing studies (Biesecker et al., 2011), there
is a newfound access to samples with low minor allele frequency (MAF 1− 5%) and rare
(MAF < 1%) genetic variants. In the search for genetic components of complex traits,
discovered common variants (MAF > 5%) from genome-wide association studies explain
only a small proportion of the total heritability of these traits (Ioannidis et al., 2009; Ma-
her, 2008; Manolio et al., 2009). As a result, attention has turned to low frequency and rare
variants instead expecting that they could play an important role in uncovering gene-
phenotype relationships (Cirulli and Goldstein, 2010; Ji et al., 2008; Nejentsev et al., 2009;
Ng et al., 2008; Ramser et al., 2008). Unfortunately, rare variants are difficult to detect
in even reasonably large samples. This problem can be alleviated through the develop-
ment of powerful study designs. To this effort, numerous association studies have chosen
to sample subjects with extreme phenotypes in the hope of increasing power to detect
causal SNPs (Cle´ment et al., 1995; Gu et al., 1997; Hu et al., 2009; Khor and Goh, 2010;
Li and Leal, 2008; Liang et al., 2000; Price et al., 2010; Risch and Zhang, 1995). There
have also been numerous developments in methodology to detect QTLs under these ex-
treme phenotype sampling (EPS) study designs(Chen et al., 2005; Huang and Lin, 2007; Li
et al., 2011; Slatkin, 1999; Wallace et al., 2006). A fundamental assumption that motivates
these EPS methods is that rare causal variants are more likely found in the extremes of
the quantitative trait. In this paper, we support the use of this practice by showing both
analytically and numerically that EPS increases the presence of rare causal variants in a
variety of settings. As a result, we show that EPS is more powerful for detecting for rare
variant effects than random sampling.
Various methods have been proposed to tackle the challenge of association testing
for rare variants. Burden tests such as the Combined Multivariate and Collapsing method
(CMC) (Li and Leal, 2008), Cohort Allelic Sums Test (CAST) (Morgenthaler and Thilly,
2007) and the Weighted Sum Test (WST) (Madsen and Browning, 2009) combine informa-
tion from all rare variants within a target region such as an exon or gene by collapsing
them into a single genetic variable, which is tested for association with the phenotypes of
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interest. Numerous rare variants testing methods have been developed using the same
strategies (Bansal et al., 2010; Basu and Pan, 2011; Lee et al., 2012a; Morris and Zeggini,
2010; Price et al., 2008). A limitation of all burden tests is that they could lose significant
amount of power in the presence of variants with different association directions and a
large fraction of non-causal variants in the region. Alternatively the Sequence Kernel
Association Test (SKAT) (Wu et al., 2011a) aggregates evidence of individual variant ef-
fects across the region using a kernel function and uses a computationally efficient mixed
model variance component test to test for association. SKAT can naturally adjust covari-
ates and has robust power in the presence of variants with different association directions
and a large proportion of null variants. It is also a generalization of several non burden
tests such as C-alpha test (Neale et al., 2011), the SSU test (Pan, 2009), and the haplotype
association test (Tzeng and Zhang, 2007). Recently the optimal SKAT (SKAT-O) (Lee et al.,
2012b) has been proposed to unify the burden test and SKAT to a single framework and
to construct the optimal test within the framework.
Moreover, limited statistical methods have been developed for studying rare vari-
ant effects when extreme phenotypes are sampled. In a typical EPS study, the two ex-
tremes are treated as two different groups representing a dichotomous phenotype. For
example, Hu et al. (Hu et al., 2009) used the contrast between subjects with high HDL-C
levels against those with low HDL-C levels to identify an association with the ABCA1
gene. If the same method of extreme sampling were to instead retain the continuous
phenotype values, the gain in information could provide greater power to detect gene-
phenotype associations. For common variants, Huang and Lin (Huang and Lin, 2007)
proposed testing for associations between extreme continuous phenotypes and variants
using the maximum likelihood method assuming a truncated normal distribution for ex-
treme phenotype. Recently, this approach was adapted by Li et al. (Li et al., 2011) to
accommodate testing for multiple rare variant effects with the burden CMC approach.
As a burden test, this approach is powerful when most variants in a region are causal and
the effects of causal variants are in the same direction. However, it loses power in the
presence of variants with different association directions or a large number of non-causal
variants in a region.
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In this paper, we first confirm both analytically and empirically that EPS substan-
tially increases the chance to observe rare causal variants and hence increases their ob-
served frequencies in finite study samples. Using this result, we demonstrate that EPS
provides a more powerful design strategy for testing rare variant effects compared to
random sampling. We next develop a new more powerful statistical method for testing
for rare variant effects in EPS. Specifically, we extend SKAT and the optimal SKAT (SKAT-
O) to EPS by analyzing extreme phenotypes as continuous variables within a likelihood
framework. We show that the proposed tests perform well in a wide range of situations
and outperform burden tests. We further show that analysis using continuous extreme
phenotypes (CEP) improves power for detecting rare variant effects compared to using
dichotomized extreme phenotypes (DEP). We illustrate the finite sample performance of
proposed methods by conducting extensive simulations and application to analysis of
triglyceride levels from the Dallas Heart Study (Victor et al., 2004).
1.2 Material and Methods
1.2.1 Goals and notation
The goal is to find an optimum sampling strategy when resources are limited and
to develop powerful association test methods to detect phenotype-genotype associations.
We evaluate the effectiveness of extreme phenotype sampling (EPS) compared to random
phenotype sampling.
We first confirm analytically that extreme phenotype sampling enriches causal rare
variants by increasing their MAFs (Appendix A.1). We consider the cases with a single
causal variant and multiple causal variants and calculate the MAF in extreme phenotype
sampling as a function of the population MAF, the threshold used to select extreme phe-
notypes, and the effect sizes of genotypes.
We next evaluate the two different methods that utilize EPS phenotypes in different
ways: the method that retains continuous phenotypes and the method that dichotomizes
them into cases and controls. We consider the case with a sample of n individuals who
have been sequenced in a genomic region of interest containing p genetic variants. The
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ith individual has covariate information over m covariates Xi = [Xi1, , Xim]T , genotypes
of the p variants in the region Gi = [Gi1, , Gip]T , and a continuous phenotype yi. The
genotype Gij represents the number of copies of the minor allele of the jth variant that
the ith individual has.
1.2.2 Model
To test for an association between the variants and continuous phenotype while
controlling for covariates, consider a linear model
yi = α0 +α
′Xi + β′Gi + i
where i ∼ N(0, σ2). Here α0 is an intercept term, α = [α1, ..., αm]′ is a vector of re-
gression coefficients for p genetic variants. The null hypothesis of H0 : β = 0 corresponds
to no genetic effect on the trait. Since a p-DF likelihood ratio test has little power to detect
causal variants particularly in the presence of a large number of rare variants, the gene-
phenotype relationship is instead tested for by region-based tests such as burden tests
and non-burden tests, e.g., SKAT. An adaptation of the CMC (Li and Leal, 2008) burden
test is used that collapses genotype information by counting the number of variants in
the region before applying logistic regression to the collapsed statistic. We call this test
DEP-Burden.
1.2.3 Association tests under the extreme phenotype sampling design
Since both SKAT and burden tests are capable of handling dichotomous pheno-
types in the case-control setting, they can be applied to test for associations after using
EPS. Dichotomizing the high phenotypic extremes as cases and the lower phenotypic ex-
tremes as controls is a natural extension of each tests functionality. However, applying
SKAT and SKAT-O to continuous phenotype data obtained from EPS requires further
development, since the extreme continuous phenotypes do not follow Gaussian distribu-
tion due to the phenotypic selection. Suppose we select n samples with either yi > c1
or yi < c2, and denote the selected yi as y∗i . Then under the null hypothesis y∗i follows
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truncated Gaussian distribution with a density function
f(y∗i ) =
φ(Xiα, σ
2)
Φ(c2, σ2) + 1− Φ(c1, σ2)
where φ(µ, σ2) and Φ(µ, σ2) are density and distribution functions of the Gaussian
distribution with mean 0 and variance σ2.
To increase test power and decrease the test DF, we assume βj follows an arbitrary
distribution with mean 0 and variance ψw2j . We note that H0 : β = 0 is equivalent to
H0 : ψ = 0. The score test statistic of ψ = 0 is
Qs =
p∑
j=1
w2j
(
n∑
i=1
Gij(y
∗
i − µˆi)
)2
where µˆj is an estimated mean of y∗i under the null hypothesis. We now show that
Qs asymptotically follows a mixture of chi-squares distribution.
1.2.4 The null distribution of Continuous Extreme Phenotype SKAT
Suppose the null model is true where β = 0 and where Xi = [xi0, ..., xim]′ are
covariates of the ith individual with xi0 = 1 andα = [α0, ..., αm]′ is the vector of regression
coefficients of Xi and i ∼ N(0, σ2). Suppose we select n samples with either yi > c1 or
yi < c2, and denote the selected yi as y∗i . Under the null hypothesis, y∗i follows a truncated
Gaussian distribution with density function
f(y∗i ) =
1√
2piσ2
−(y∗i −X ′iα)2/2σ2
Φ(ti2) + 1− Φ(ti1)
where ti1 = (c1 −X ′iα)/σ and ti2 = (c2 −X ′iα)/σ. The first derivative of the log-
likelihood function is
uj =
dL
dαj
=
1
σ2
n∑
i=1
xij(yi −X ′iα+mi)
and the second derivative is
Jjk =
d2L
dαjdαk
=
1
σ2
n∑
i=1
xijxik(−1 + vj)
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where
mi = σ
φ(ti2)− φ(ti1)
Φ(ti2) + 1− Φ(ti1) , and vi =
ti2φ(ti2)− ti1φ(ti1)
Φ(ti2) + 1− Φ(ti1) +
m2i
σ2
Define S = −J , y∗ = [y∗1, ..., y∗n]′, u = [u0, ..., um]′, and m = [m1, ...,mn]′. By Fisher
Scoring (or Newton Raphson) procedure, a new α is
α∗ = α+ S−1u
hence S(α∗ − α) = u. Since S = X ′V X/σ2, where V = diag{(1 − vi)} and
X = [X1, ...,Xn]
′,
X ′V X(α∗ −α) = X∗(y∗ −Xα−m)
Now treat the Fisher Scoring algorithm as a weighted least squares problem. Define
the working vector
y˜ = Xα+ V −1(y∗ −Xα−m)
,
and then α∗ is a weighted least squares estimator of the linear model y˜ = Xα + ˜
with E(˜) = 0 and V ar(˜) = V −1. Since E(y∗i ) = X∗i α −mi, the SKAT test statistic with
linear weighted kernel is
Qs = (y
∗ − µˆ)′GWG′(y∗ − µˆ)
= (Y˜ −Xα∗)′V GWG′V (Y˜ −Xα∗)
= Y˜ P0GWG
′P0Y˜
where P0 = V − V X(X ′V X)−1X ′V . From V ar(y˜i) = (1 − vi)σ2, the asymptotic
null distribution of Qs is
∑
λvχ
2
v
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where λv is the vth eigenvalue of σˆ2P
1/2
0 GWG
′P 1/20 .
Calculations of Qs require fitting the null model using extreme phenotypes y∗i un-
der truncated normal likelihood. The Newton-Raphson method can be used to estimate
α and σ2. P-values can be obtained by approximating the mixture of chi-square distribu-
tions with a non-central chi-square distribution by matching he moments or inverting the
characteristic function (Davies, 1980).
1.2.5 Optimal Continuous Extreme Phenotype SKAT
Recently Lee et al. (2012) (Lee et al., 2012b) proposed an optimal unified approach,
which unifies SKAT and burden test to adaptively select best test structure, called SKAT-
O. We can not only extend SKAT, but also SKAT-O to continuous extreme phenotypes.
Suppose QB is the score test statistics of the weighted burden test:
QB =
(
n∑
i=1
(y∗i − µˆi)
p∑
j=1
wjGij
)2
and then the test statistic of unified test is
Qρ = (1− ρ)Qs + ρQB
where ρ (0 ≤ ρ ≤ 1) is a parameter to determine whether test is close to SKAT
(ρ = 0) or burden tests (ρ = 1). It is based on a recent generalization of SKAT which
allows the correlation among variants effects βs. Under this setting, they proposed the
optimal SKAT, called SKAT-O. This test is defined by selecting the ρ that minimizes the
p-value of the SKAT-O test statistic,
T = min
0≤ρ≤1
pρ
where pρ is a p-value with given ρ. The test statistic T can be obtained by sim-
ple grid search across a range of ρ: set a grid 0 = ρ1 < ρ2 < · · · < ρb = 1, then
T = min(pρ1 , ..., pρb). In simulation studies and real data analysis, we used the equal
sized grid of 11 points (from 0 to 1) to obtain T . From the fact that the Qρ can be decom-
posed to the shared random variables, asymptotic p-value of T can be obtained through
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computationally efficient one-dimensional numerical integration (Appendix A.2). We use
this extreme phenotype optimal SKAT in our simulation studies and data analysis.
When the sample size is small, SKAT family methods (including SKAT and SKAT-
O) can produce conservative results with both binary and extreme continuous pheno-
types. To resolve this issue, Lee et al. (Lee et al., 2012b,a) have proposed a method
to adjust asymptotic null distribution by estimating small sample moments when the
trait is dichotomous. We employ a similar approach (Appendix A.3). For all simula-
tion studies and real data analysis we used small sample adjustment for SKAT meth-
ods given the small to moderate sample sizes we considered. We used SKAT-O for con-
tinuous extreme phenotype SKAT (CEP-SKAT-O) and dichotomous extreme phenotype
SKAT (DEP-SKAT-O), and for random sample continuous phenotypes (RS-SKAT-O). It
should be noted that for larger sample sizes, the small sample adjustment is not neces-
sary. Through simulations we found sample sizes lower than n=500 to benefit from the
small sample adjustment, with sample sizes as low as n=1000 to not benefit from the
adjustment.
1.2.6 Type I error simulations
We first generated haplotype data by the forward simulator, SFS CODE (Hernan-
dez, 2008), which offers the ability to incorporate purifying selection on deleterious vari-
ants and thus provides better model to simulate variants in exomes. Data were simulated
according to the European demographic model with a population bottleneck followed by
exponential growth. We simulated 32,000 haplotypes each 100,000 base pairs wide as our
population base. To achieve a simulated sample over a 3kb exon, a random 3kb region is
selected (containing 41 variants on average) and each individual genotype is formed by
combining at random two haplotypes over that region. Phenotypes for the i-th individual
in a sample were produced from the generated genotype and covariate data according to
Yi = 0.5Xi1 + 0.5Xi2 + i
Where the covariate Xi1 is 1 with probability 0.5 and 0 otherwise, and the covariate Xi2
and the residual i are both instances of a standard normal random variable.
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Using the simulated genotype and phenotype data for theN individuals, a random
sample of size n is selected. For random sampling of continuous traits, SKAT-O with the
default wj = Beta(1, 25) weight is used to test for an association between the continuous
phenotype and genotype after controlling for both covariates, producing a p-value (RS-
SKAT-O) . In order to test for the association between variants and phenotype under EPS
using the standard dichotomizing method, we treat the highest (n/2) extremes as cases
and lowest (n/2) extremes as controls. The dichotomized phenotypes are used by both
DEP-SKAT-O and DEP-Burden. This same extreme phenotype sample is used to compare
with the tests that retain the continuous phenotype (CEP-SKAT-O and CEP-Burden). A p-
value for the CEP-SKAT-O test and the CEP-Burden burden test are produced from these
continuous phenotype values and the corresponding genotype and covariate data. The
proportion of p-values below a specified α-level provides an estimate for the Type I error
at that significance level.
1.2.7 Power simulations
Power comparisons between the various sampling methods were performed using
simulated genotype data as was used in the Type I error simulation setting. After gener-
ating the genotypes for N individuals, 20% of the variants with MAF < 0.03 are selected
to be causal variants. Different percentages of causal variants were also considered. Phe-
notypes are then generated for the N individuals according to:
y = 0.5X1 + 0.5X2 + β1G1 + ...+ βpGp + 
The covariate X1 is generated as a Bernoulli random variable with p = 0.5. The covariate
X2 and the added noise  are generated independently from a standard normal distri-
bution. Non-causal variants are assigned βj = 0, and the causal variants are generated
according to:
|βj| = −alog10(MAFj)
Here, a > 0 is a parameter that specifies the strength of variant-phenotype associations,
hence the strength of heritability. Large values of a lead to stronger effects of causal vari-
ants on phenotype and cause rare variants to become more enriched in the phenotypic
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extremes. In one simulation setting an increase in a from 0.3 to 0.4 increases the heritabil-
ity of the phenotype from 0.034 to 0.042. The heritability also increases with the number
of causal variants. To obtain an estimate of the heritability, the proportion of the variance
in phenotype explained by the genotypes of causal variants is estimated assuming no LD
between variants.
Power estimates are obtained for various (extreme phenotype) sample sizes (n=500,
1000, and 2000), percentages in each phenotypic extreme sampled (10% and 25%), per-
centages of causal variants with a positive effect (80%, 100%), and percentages of causal
variants with MAF < 0.03 (20%, 40%, and 60%).
1.3 Results
1.3.1 Extreme sampling enriches rare causal variants
Our analytical calculations (See Material and Methods and Appendix A.1) confirm
that rare causal variants can be enriched in phenotypic extremes. The degree of enrich-
ment increases when more extreme phenotypes are sampled and a higher percentage of
causal variants are present in a region. To empirically validate this finding, randomly se-
lected 3kb exonic regions were simulated using the population genetic simulation model
with European demographic history (see Material and Methods). For each 3kb region,
causal variants were randomly selected to be 100%, 70%, 40% and 0% of sufficiently rare
variants (MAF < 0.03) and the jth causal variant was given the effect size βj as a func-
tion of its MAF. Note that these causal variant percentages differ from those in the power
simulations so as to further accentuate the effect of causal variant percentage on the in-
flation of MAF due to EPS. Also for the power simulations, causal variant percentages of
10% and 20% were used instead. Phenotypes are then generated from a linear model with
heritability of genetic variants being 2.6%, 1.3%, and 0%.
Because the causal variants are known in the simulation setting, the expected MAF
of a causal variant using EPS can be computed analytically (Appendix A.1). The expected
MAFs of causal variants using EPS matched closely with the sample MAFs of causal vari-
ants using EPS (Figure 1.1). The MAFs of simulated causal variants after EPS had an
11
Figure 1.1: Estimated folds increase of the observed MAFs of causal variants in pheno-
typic extremes over population MAFs. The red lines represent the smoothed observed
fold increases. The dotted lines represent the theoretical fold increase. For each causal
variant, population MAF was computed using the full simulated population while ex-
treme phenotype MAF was computed after sampling the tails. See Appendix A.1 for
derivation of theoretical expected MAF for extreme phenotypes. The top two figures con-
sider the case where all variants are causal by sampling k = 10% and 20% high/low ex-
tremes. For each case, three situations were considered by heritability of causal variants:
H2 = 2.6%, 1.3%, and 0% (no causal variant). Higher heritability gives more enrichment
of rare variants. The bottom two figures consider the case where different fractions of
variants in a region are causal (100%, 70%, 40% and 0%) by sampling k = 10% and 20%
high/low extremes. Presence of non-causal variants in a region lower the degree of en-
richment of rare variants.
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overall increased frequency over the respective population MAFs. This trend decreases
as samples are restricted to less extreme phenotypes and heritability is lower. No enrich-
ment is found when there is no causal variant. When both the causal and non-causal
variants in a region are considered simultaneously, the median MAF using EPS is much
less inflated than when only causal variants are examined.
1.3.2 Sampling methods for comparison
Motivated by the enrichment of causal rare variants in phenotypic extremes, we
expect to find that EPS methods can increase power to detect rare causal variants over
random sampling methods. We extend the SKAT family methods to test for region-level
rare variant effects when continuous phenotypes obtained from EPS are used in analy-
sis. In simulation and data analysis, we only use the extreme phenotype optimal SKAT
(SKAT-O), which accounts for extreme phenotype sampling and unifies the burden test
and SKAT to a single framework and by constructing the optimal test within the frame-
work. Using the simulated genotype data over 3kb regions the phenotypes were gener-
ated using the additive linear model (see Material and Methods). Given the same sample
size, we compare the power of three tests designed for detecting rare variant effects using
EPS. We first consider a burden test, DEP-Burden, that uses dichotomized extreme pheno-
types along with collapsed information over genotypes by simply counting the number
of rare variants with MAF < 3% in the gene before applying logistic regression to the
collapsed statistic. We also apply this same collapsed statistic to continuous extreme phe-
notypes as done in Li et al. (Li et al., 2011) and call this test CEP-Burden. Next we consider
dichotomized extreme phenotype SKAT-O (DEP-SKAT-O), which applies optimal SKAT
(SKAT-O) to dichotomized extreme phenotypes while applying small sample adjustments
when sample sizes are small (Lee et al., 2012a). Finally we consider continuous extreme
phenotype SKAT (CEP-SKAT-O), which does not dichotomize and instead extends lin-
ear regression optimal SKAT over the continuous extreme phenotypes (see Material and
Methods) by using a truncated normal distribution. We also applied the small sample
adjustment to CEP-SKAT-O to obtain the correct type I error rates when sample sizes are
small. To demonstrate the benefits of EPS compared to random sampling, we included in
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the comparison a fourth method using random sampling SKAT-O (RS-SKAT-O), which
applies optimal SKAT to the continuous phenotypes of a random sample. We assume the
same sample size when comparing different methods so their powers are comparable.
The power of each competing method is estimated as the proportion of p-values less than
α = 10−6 in an effort to imitate genome-wide association studies.
The type 1 error rates for CEP-SKAT-O were accurate at α = 0.01 and α = 0.05 and
slightly inflated at genome-wide significance levels α = 10−6(see Table A.1). When all
causal variants had the same direction of effect, CEP-SKAT-O and CEP-Burden had the
greatest power with a substantial lead over every other method (Figure 1.2). When causal
variants had effects in opposite directions all tests lost power uniformly due to less en-
richment of rare variants, but CEP-SKAT-O became the most powerful by a large margin
(Figure 1.3). In this case DEP-Burden had the least power. The power of the three methods
employing SKAT-O (CEP-SKAT-O, DEP-SKAT-O, and RS-SKAT-O) is much more robust
to changes in the proportion of causal variants that have a positive effect than the burden
tests power is. This is because SKAT-O allows for each individual variant to affect pheno-
type in different directions and also allows for no effect. On the other hand, burden tests
assume all the causal variants share the same direction of effect and that all the variants in
a region are causal, and so the power of the burden tests greatly diminishes when causal
variants are allowed effects in opposite directions or many causal variants are allowed no
effect.
When all causal variants having the same direction of effect and as the percent of
rare variants that were causal increased, the power gap between DEP-Burden and DEP-
SKAT-O reduces, an observation that is also true for the relationship between CEP-Burden
and CEP-SKAT-O (Figure 1.2). This is because CEP-SKAT-O includes CEP-Burden as a
special case and behaves like CEP-Burden automatically when most variants are causal
with effects in the same direction. To see this, we found that in simulations the estimated
ρ decreased by a factor of 0.36 on average when changing from the case of having all
positive causal variant effects to the case of having causal variant effects in opposite di-
rections.
Methods utilizing extreme sampling benefit as the cutoff for extreme phenotypes
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Figure 1.2: Simulated power comparisons between four rare variants association tests
with all causal variants having a positive effect on phenotype. The five tests are ran-
dom sample optimal SKAT (RS-SKAT-O), dichotomized extreme phenotype burden test
(DEP-Burden), continuous extreme phenotype burden test (CEP-Burden), dichotomized
extreme phenotype optimal SKAT (DEP-SKAT-O), and continuous extreme phenotype
optimal SKAT (CEP-SKAT-O). The left panel considers the situation where 10% high/low
extremes are sampled with the three rows corresponding to 20% (0.6% heritability), 40%
(1.2% heritability) and 60% (1.8% heritability) variants in a 3kb region being causal. Three
total sample sizes are considered: n = 500, 1000, 2000. The right panel considers the sit-
uation where 25% high/low extremes are sampled. Exonic regions are simulated with
effect sizes for each causal variant equal to β = −0.2log10MAF . Power is estimated by
the proportion of tests that detect an association at the α = 10−6 level.
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Figure 1.3: Simulated power comparisons between four rare variants association tests
with 80% of rare causal variants selected to have a positive effect on phenotype while
the remaining 20% have a negative effect. The five tests are random sample SKAT (RS-
SKAT-O), dichotomized extreme phenotype burden test (DEP-Burden), continuous ex-
treme phenotype burden test (CEP-Burden), dichotomized extreme phenotype optimal
SKAT (DEP-SKAT-O), and continuous extreme phenotype optimal SKAT (CEP-SKAT-O).
The left panel considers the situation where 10% high/low extremes are sampled with
the three rows corresponding to 20% (0.6% heritability), 40% (1.2% heritability) and 60%
(1.8% heritability) variants in a 3kb region being causal. Three total sample sizes are con-
sidered: n = 500, 1000, 2000. The right panel considers the situation where 25% high/low
extremes are sampled. Exonic regions are simulated with effect sizes for each causal vari-
ant equal to |β| = −0.2log10MAF with the effect being negated 20% of the time. Power is
estimated by the proportion of tests that detect an association at the α = 10−6 level.
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increases. In particular, as the percent of the tails sampled from the distribution of pheno-
type decreases from 25% to 10%, all EPS tests show incremental increases in power given
the same sample size due to higher enrichment of rare variants. Relative power com-
parisons remain unchanged after decreasing the heritability of the phenotype and after
increasing the exon length to 5kb or 10kb (regions of these lengths contain 69 variants and
138 variants on average, respectively). Also, simulations were also performed where the
β was selected to be a constant rather than being a decreasing function of the MAF but
the relative power of the methods remained the same (Figure A.3). Regardless of the set-
ting, CEP-SKAT-O was consistently robust and had the greatest overall power to detect
gene-phenotype associations over the other methods.
1.3.3 Application to the Dallas Heart Study data
In the Dallas Heart Study (Victor et al., 2004), 3476 individuals were sequenced
over the genes ANGPTL3 (MIM 604774), ANGPTL4 (MIM 605910), and ANGPTL5 (MIM
607666). A total of 93 variants are present over these genes, and the variants in all three
genes were tested simultaneously for an association with log-transformed serum triglyc-
eride levels (logTG). Analysis for each of three genes separately is also considered (Ap-
pendix A.5). Ethnicity and sex were adjusted for in the analysis. To demonstrate rare
variant association test methods for extreme phenotype sampling (EPS), a total of 1389
individuals with the highest 20% and lowest 20% of logTG levels in each age-gender stra-
tum were selected as the EPS sample. The continuous values were used in CEP-SKAT-O
while dichotomized values were used for DEP-SKAT-O and DEP-Burden. Random sam-
ples of equivalent size were selected for the RS-SKAT-O method for comparison purposes.
To compare the effects of the different cutoffs of tails, we considered to sample
individuals from wider tails (30% and 40%). Since wider tails had more samples, to make
p-values comparable, we randomly sub-sampled 1389 individuals among individuals in
wider tails in order to have the same sample size as compared to a 20% cut off. In these
cases, median p-values calculated from multiple random samples were obtained (Table
A.2). The p-values for all EPS methods are sensitive to the extreme phenotype cutoff.
CEP-SKAT-O outperforms the other methods when there is sufficient information about
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the continuous trait distribution. It performs similarly to DEP-SKAT-O where there is
limited information in the data, e.g., when the cutoff is low or when there are a small
number of rare variants in a gene (Appendix A.5). When extremes were sampled from
wider tails (30% and 40%) all of the tests tended to lose significance, demonstrating the
strength of EPS. We also computed p-values with different cutoffs and unequal sample
sizes (Figure A.2), and CEP-SKAT-O outperformed other competing methods overall.
1.3.4 Power estimation
In the planning of new sequencing studies, it is important to be able to estimate
the power to detect causal variants under various study designs. We provide such power
calculations for extreme phenotype sampling designs using CEP-SKAT-O. We use ana-
lytical formulas to obtain the distribution of our statistic by allowing users to specifying
desirable parameters of interest (Appendix A.4). The parameters that can be specified
by the user include sample size, the percent of causal variants, the length of the genomic
region, the effect size of the causal variants, the proportion of causal variants that have
a positive effect, and the proportion of the tails that are sampled in EPS. We find that
power is increased as sample size increases, as the proportion of causal variants increases,
as the effect size increases, when causal variants have their effect in the same direction,
and when we are more selective by sampling individuals with more extreme phenotypes.
The power is also dependent on the genomic region as the distribution of the number of
genetic variants, the MAF distribution, and the LD structure vary over the genome, so
for genome-wide studies power estimations are averaged over many randomly selected
regions of equivalent size.
To evaluate the accuracy of these analytic power estimations, we show a side by
side comparison with empirical power simulations (Figure 1.4 and Figure A.1). In this
setting we consider 3kb regions with 20% of variants being causal with all effects in the
same direction. We see that the estimated power with our analytic calculations matches
the empirical power over a wide range of sample sizes.
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Figure 1.4: Estimated power of CEP-SKAT for testing 3kb regions with 20% of variants
being causal with all effects in the same direction and the casual variants have effects
to |β| = −0.2log10MAF . Theoretical power was calculated as described Appendix A.5,
and empirical power was estimated by simulation using 300 replicates. No covariates
were considered in either the theoretical or empirical power calculations. Furthermore
empirical power was computed using CEP-SKAT without small sample adjustments.
1.4 Discussion
We confirm in this paper through analytical calculations and simulation studies
that sampling phenotypic extremes of a population can enrich rare causal variants. As
a consequence, we show that sampling from phenotypic extremes profit over analogous
random sampling methods by showing a sizable gain in power when the same size is
used. In particular, analysis using dichotomized extreme phenotype (DEP-SKAT-O) is
shown to be more powerful than that using random sampling with continuous phe-
notypes (RS-SKAT-O) in almost all scenarios. We develop a new method, continuous
extreme phenotype optimal SKAT (CEP-SKAT-O), which improves upon DEP-SKAT-O
by retaining continuous phenotype information rather than dichotomizing, includes the
continuous extreme phenotype burden test as a special case, and results in a significant
increase in sensitivity to causal variants. We find that CEP-SKAT-O has the overall great-
est power in a wide variety of settings over DEP-SKAT-O, RS-SKAT-O, and comparable
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collapsing methods.
In the realm of region based association testing methodology, there already exist
many methods capable of handling continuous phenotypes when a normal distribution
is assumed. However in the case of extreme sampling, phenotype follows a truncated
normal distribution instead, and so current methods cannot be directly applied without
dichotomizing. The advantage of CEP-SKAT-O is that it adapts SKAT-O, a method that
applies multiple linear regression of a phenotype on all genotypes in a region, to be able to
handle phenotypes coming from a truncated normal. This adaptation allows for the usual
continuous phenotype analysis without forcing the usual loss of phenotype information
that occurs due to dichotomizing.
CEP-SKAT-O assumes that subjects are sampled from the extremes of a normally
distributed phenotype, which in some circumstances may be inappropriate, and hence
the test results can be biased when the normality of the underlying trait is violated. Di-
chotomizing phenotypes using DEP-SKAT-O is robust to departure from normality, al-
though it is subject to some power loss when normality assumption is true. For candidate
gene studies, permutation can be used to estimate the null distribution of the CEP-SKAT-
O test statistic when the underlying trait does not follow a normal distribution. However,
this is computationally difficult for GWAS where genome-wide significance levels are
very stringent and a large number of genes are tested. We have found the maximum like-
lihood estimator of 2 seems to be sensitive to the distribution of the underlying trait. It is
of future research interest to develop an alternative estimator of 2 that is more robust to
deviations from normality.
In several ongoing exome sequencing studies conducted in the NHLBI Exome Se-
quencing Project, subjects were sampled using extremes of multiple phenotypes, future
research is needed to develop methods for analyzing this more complex sampling setting.
When subjects with extreme phenotypes are sampled for sequencing, covariate confound-
ing effects need to be accounted for at the design phase to ensure representative samples.
One strategy is to use stratified sampling, i.e. sample extreme phenotypes within key
covariate stratum. For example, a phenotype distribution is likely to be gender-specific.
It is desirable to sample extreme phenotypes within each gender stratum. The residual
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covariate confounding effects can be adjusted for at the analysis stage.
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2.1 Introduction
The higher criticism is a method to test for the joint null hypothesis against the
alternative hypothesis that signals in a set are sparse. This situation is commonly encoun-
tered in genetic association studies, where it is often of interest to jointly test the effects of
genetic variants within a gene, network, or pathway on a disease/trait (Tzeng and Zhang,
2007; Wu et al., 2011b). The higher criticism adaptively aggregates independent marginal
test statistics, and has been shown to be an asymptotically powerful test of the joint null
hypothesis when signals are sparse and are above the detection boundary (Donoho and
Jin, 2004; Arias-Castro et al., 2011). Here “asymptotics” refers to the number of test statis-
tics, d, tending towards infinity. The higher criticism test statistic is the supremum of a
standardized empirical process under the null hypothesis and follows a Gumbel distri-
bution asymptotically, but its convergence is very slow and its p-value cannot be reliably
computed analytically based on asymptotic theory unless d is very large (Jaeschke, 1979).
However, many practical situations of interest that could benefit from the higher
criticism do not have a very large d. For example, in genome-wide association studies,
one is often interested in testing for the effect of genetic variants in a gene or a pathway.
The number of genetic variants in a gene or a pathway is often not large, e.g., the number
of genetic variants in a gene is often in the dozens for the vast majority of genes across
the genome and the number of genetic variants in most genetic pathways is often in the
hundreds. To test for the joint null hypothesis of no gene or no pathway effect, the asymp-
totic theory based p-values using the higher criticism are not applicable due to its very
slow convergence rate. Simulation of the null distribution might seem a reasonable al-
ternative to asymptotics. However, this is computationally burdensome in genome-wide
association studies, as tens of thousands of genes of different sizes need to be tested, and
a control for multiple comparisons results in very stringent significance levels. For exam-
ple, in order to obtain p-values accurate to the genome-wide significance level of 10−7 for
testing 104 genes requires at least a staggering 1011 total test statistics simulated under the
null hypothesis.
We present in this paper an analytic method of accurate p-value calculations for the
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higher criticism in non-large d signal detection settings. The proposed method relies nei-
ther on asymptotics in d nor on computationally expensive simulation of the null distri-
bution. We show the proposed method is exact for an arbitrary d for normally distributed
marginal test statistics, and is computationally fast for the non-large d settings commonly
encountered in genome-wide association studies. We evaluate the finite sample perfor-
mance of the proposed method using simulation and demonstrate the effectiveness of the
method on data from a case-control lung cancer genome-wide association study.
2.2 The higher criticism and its asymptotic distribution
Consider d normally independent test statistics Z = [Z1, ..., Zd]T with means µ =
[µ1, ..., µd]
T and unit variance. It is of interest to test the joint null hypothesis that H0 :
µ = 0 against the alternative that µ is a sparse vector with the number of non-zero entries
d0 = d
1−β (β ∈ (1/2, 1)) (Donoho and Jin, 2004). Letting Φ¯(t) be the survival function of the
standard normal distribution and S(t) =
∑d
j=1 I{|Zj |≥t}, the higher criticism test statistic is
HC = sup
t>0
(
S(t)− d2Φ¯(t)
[d2Φ¯(t){1− 2Φ¯(t)}]1/2
)
. (2.1)
Under the null, HC follows a Gumbel distribution as d → ∞. For large d, gains in
power can be made by searching for the supremum over a restricted range of t (Donoho
and Jin, 2004). For 0 <  < δ < 1, if the supremum in (2.1) is taken over the interval
Φ−1(1 − δ/2) < t < Φ−1(1 − /2) then as shown in Jaeschke (1979), we can approximate
the distribution of HC using its asymptotic distribution
pr(HC < c) ≈ exp[− exp{−c(2logρ)1/2 − 2−1logpi + 2−1log2ρ+ 2logρ}], (2.2)
where ρ = 2−1log[δ(1 − )/{(1 − δ)}]. Jaeschke (1979) shows that the higher criticism
converges in distribution at an abysmal rate of O{(logd)−1/2}. Our simulations show that
the asmyptotic distribution is inaccurate for d as large as 106 (Appendix B.3). As a result,
accurate higher criticism p-values at stringent significance levels for gene or pathway
level analysis in genome-wide association studies need to be acquired without the use of
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asymptotics.
In genetic association studies, the individual marker test statistics Zj within a gene
or a genetic pathway are often correlated with covariance Σ, which can be estimated from
the genotypes of a study sample. Letting UUT = Σ be the Cholesky decomposition, then
under the joint null hypothesis, the transformed statistics U−1Z are uncorrelated standard
normal random variables and so the higher criticism can be applied directly on these
transformed test statistics (Hall and Jin, 2010). This is appropriate only when sample size
is larger than d, which is often the case in gene/pathway level analysis in genome-wide
association studies.
2.3 Estimation of p-values for the higher criticism in finite
d settings
The higher criticism test rejects the joint null hypothesis for large values ofHC. We
show in this section, finding the supremum does not require an exhaustive search over
all t > 0. Let HC(t) = {S(t) − d2Φ¯(t)}[d2Φ¯(t){1 − 2Φ¯(t)}]−1/2. Then HC(t) is a piecewise
increasing function with a local maximum at each observed |Zi|. Hence calculating the
supremum in the higher criticism test statistic requires only finding a maximum over
d quantities. Specifically, let h be the observed HC statistic in (2.1). Letting c(t|h) =
h[2dΦ¯(t){1 − 2Φ¯(t)}]1/2 + 2dΦ¯(t), the p-value corresponding to a given observed higher
criticism statistic h is
pr
[
sup
t>0
{HC(t)} ≥ h
]
= 1− pr
[⋂
t>0
{S(t) < c(t|h)}
]
. (2.3)
Upon first glance, evaluating the p-value in (2.3) seems to require determining the prob-
ability of an intersection of an uncountable number of events (one for each t > 0). With-
out having asymptotics in d, we can instead leverage the fact that S(t) is binomially dis-
tributed and can only take on a finite number of values 0, ..., d. This will reduce the inter-
section in (2.3) to an intersection over a finite number of events as defined by the partition
given in Lemma 1.
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Figure 2.1: An example c(t|h) = h[2dΦ¯(t){1− 2Φ¯(t)}]1/2 + 2dΦ¯(t) is plotted with d = 6 and
h = 2.4. The partition given by Lemma 1 is labeled on the t-axis.
Lemma 1. There exists a partition of the positive real line 0 = t0 < · · · < td+1 = ∞ such that
c(t|h) > d for t0 < t < t1 and d− k < c(t|h) ≤ d− k + 1 for tk ≤ t < tk+1 for each k = 1, ..., d.
The proof of Lemma 1 is left to Appendix B.2. Lemma 1 makes the observation
that c(t|h) as a function of t takes a value of d when t = 0, and then increases to a global
maximum before decreasing with an asymptote at 0 (Fig. 2.1). The form of c(t|h) is the
same for all h > 0 and so in each case the partition given by Lemma 1 exists.
We can ignore the case where the observed higher criticism statistic h = 0, because
in this case the p-value trivially takes the value of 1. For h > 0, using Lemma 1, Theorem 1
simplifies the p-value expression in (2.3) to the joint probability of a finite set which is
computationally feasible.
Theorem 1. Letting 0 = t0 < · · · < td+1 =∞ be the partition given by Lemma 1, then
pr
[⋂
t>0
{S(t) < c(t|h)}
]
= pr
[
d⋂
k=1
{S(tk) ≤ d− k}
]
.
The proof of Theorem 1 is left to Appendix B.1. According to Theorem 1 for the
partition given in Lemma 1, the p-value expression in (2.3) simplifies to
1− pr
[
d⋂
k=1
{S(tk) ≤ d− k}
]
. (2.4)
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For a given d and h, this partition is obtained by solving for tk in the equation c(tk|h) =
d− k + 1 for each k = 1, ..., d. The result is
tk = Φ
−1
[
1− 2(d− k + 1) + h
2 − h{h2 + 4(d− k + 1)− 4(d− k + 1)2/d}1/2
4(h2 + d)
]
, (2.5)
which defines the partition.
Evaluating (2.4) directly is difficult because each of the d events in the intersection
are not independent. Instead, by the chain rule for conditioning the p-value can be written
as
1− pr
[
d⋂
k=1
{S(tk) ≤ d− k}
]
= 1−
d∏
k=1
pr
[
S(tk) ≤ d− k |
k−1⋂
l=1
{S(tl) ≤ d− l}
]
. (2.6)
It is well known that empirical processes have the Markov property (Gaenssler,
1983). It follows that conditional on S(tk−1) = mk−1, ..., S(t1) = m1, then S(tk) is
Binomial with mk−1 trials and probability of success Φ¯(tk)/Φ¯(tk−1); information about
S(tk−2),...,S(t1) has no bearing on the distribution of S(tk) if S(tk−1) is known. We can
utilize this to compute the terms in the product of (2.6) by further conditioning on S(tk−1)
in the kth term. Letting qk,a = pr{S(tk) = a | S(tk−1) ≤ d− k + 1, ..., S(t1) ≤ d− 1}, some
calculations show that
qk,a =
d−k+1∑
m=0
pr{S(tk) = a | S(tk−1) = m} qk−1,m∑d−k+1
l=0 qk−1,l
=
d−k+1∑
m=0
I{a≤m}
(
m
a
)
{Φ¯(tk)/Φ¯(tk−1)}a{1− Φ¯(tk)/Φ¯(tk−1)}m−a qk−1,m∑d−k+1
l=0 qk−1,l
. (2.7)
From (2.7), in order to compute qk,a, only knowledge of qk−1,m for m = 0, ..., d − k + 1 is
required. Because q1,a = pr{S(t1) = a} is a binomial probability, this offers a base case for
calculating the p-value by computing each qk,a for k = 1, ..., d and a = 0, ..., d− k.
The main result of this paper, Theorem 2, integrates the qk,as into the exact analytic
p-value calculation of the higher criticism for an arbitrary d.
Theorem 2. For the partition in (2.5), the qk,as from (2.7), and the observed higher criticism
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d
α 2 10 50
5·0e-2 4·98e-2(5·95e-2) 4·98e-2(3·24e-2) 5·01e-2(1·84e-2)
1·0e-2 1·00e-2(2·24e-2) 9·92e-3(7·31e-3) 1·01e-2(1·59e-3)
1·0e-3 9·97e-4(2·05e-3) 1·01e-3(6·03e-4) 9·75e-4(4·90e-5)
1·0e-4 1·01e-4(5·32e-4) 1·12e-4(7·30e-5) 9·80e-5(4·00e-6)
Table 2.1: Estimated type I error rates from 106 simulations for the higher criticism using
the proposed analytic method over a range of significance levels, α. Asymptotic type I
error rates are provided for comparison: exact(asymptotic).
statistic h, the p-value for the higher criticism test statistic given in (2.1) is
pr (HC ≥ h) = 1−
d∏
k=1
d−k∑
a=0
qk,a. (2.8)
Proof. The result follows immediately by the definition of qk,a combined with Theorem 1,
equation (2.3), and equation (2.6).
Obtaining the higher criticism p-value analytically in finite samples is a three-step
process. Firstly, the observed test statistic h is computed by finding the supremum in (2.1)
which is done by finding the maximum value attained over all observed test statistics |Zi|.
Upon computing h, the partition in (2.5) is computed. Lastly, the qk,as are calculated using
this partition. As there are d(d+ 1)/2 different qk,a terms, each requiring a sum of order d
in order to be calculated, the total computation time for this last step is O(d3).
The p-value calculation has been implemented in the statistical computing soft-
ware, R, in the package GHC. The precision of this method (as well as the inaccuracy of
the asymptotic p-values) is confirmed by the Type I error simulations in Table 2.1. The
computation time in seconds for a given d on a 2·30 GHz laptop with 4 Gb memory can
be well approximated by the polynomial (3·69e-4)p - (6·98e-6)p2 + (3·63e-6)p3. This corre-
sponds to 0·007 seconds, 0·45 seconds, 28·9 seconds, and 4 hours, for d = 10, 50, 200, and
1000, respectively. For comparison purpose, we also present in Table 2.1 the empirical
type I error rates calculated using the asymptotic distribution in (2.2). The results show
they are subject to considerable bias.
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2.4 Power Simulations
We compare the power of the higher criticism to competing methods through sim-
ulation in the context of genetic association studies. An n (number of individuals) by d
(number of genetic variants) genotype matrix G is generated such that the rows are in-
dependent and the columns are autocorrelated with correlation parameter ρ. Marginally,
each Gij ∼ Binomial(2, 0·3). Letting  be the n by 1 vector of independent standard
normal noise and β be the d by 1 vector of regression coefficients, the phenotypes are
generated according to y = Gβ + . The test for the association between the jth genetic
variant and y is Zj = GTj (y − y¯)/(σˆ2GTj Gj)1/2 where Gj is the jth column of G and σˆ2 is
the sample variance.
Power is calculated for a region of size d = 40, with 10% and 5% sparsity with auto-
correlation ρ = 0, 0·05, 0·1, 0·15, 0·2, 0·25, 0·3, 0·35. In each setting, 1000 iterations resulted
in power estimates. For each iteration, causal variants were selected at random. If the
jth variant is causal, it has βj = 0·11 for the 5% sparsity case and βj = 0·08 for the 10%
sparsity case. If the jth variant is non-causal then βj = 0. In the cases where ρ > 0, the test
statistics need to first be decorrelated as in Hall and Jin (2010) so that the higher criticism
is applied instead to U−1/2Z (see Section 2). The sequence kernel association test of Wu
et al. (2011b) is provided as a comparison alongside the standard likelihood ratio test, and
the results are in Fig. 2.2.
The higher criticism has the highest power in the higher sparsity situations, while
the likelihood ratio test and the sequence kernel association test have higher power for
lower sparsity. The sequence kernel association test seems to benefit greatly from in-
creased correlation, while the higher criticism loses power as ρ increases. The reason for
this is because the transformation U−1/2Z deflates some of the signal for larger ρ, leading
to lower power. Overall, it seems that all three methods can be viable. The higher criti-
cism is a good complement to the other methods, and performs better in the presence of
weak correlation among the variants and sparse signals.
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Figure 2.2: The power of the higher criticism applied to the decorrelated test statistics
(iHC) is compared to the likelihood ratio test (LRT) and the sequence kernel association
test (SKAT). Power is simulated for each ρ that is a nonnegative multiple of 0·05 and the
smoothed results are displayed.
2.5 Data analysis
We apply our p-value computation of the higher criticism to a case-control lung
cancer genome-wide association study conducted at the Massachusetts General Hospital,
which aims at identifying genes that are associated with the risk of non-small-cell lung
cancer. The study consists of a total of 984 cases and 970 controls. We use the higher
criticism to test for the association of lung cancer risk and each gene, which consists of
multiple genetic variants. We analyze a total of 14396 genes throughout the genome with
d = 20 genetic variants per gene on average. The majority (92%) of genes have d < 50
genetic variants with the largest d being 1665.
For each gene, we calculate the marginal test statistics Zj (j = 1, · · · , d) for genetic
variant j by fitting a logistic regression model of case-control status on the genetic variant
j while controlling for age, sex, smoking, and principal components to control for pop-
ulation stratification (Price et al., 2006). As done in Section 3, the marginal test statistics
corresponding to the genetic variants within the same gene are decorrelated using the
Hall and Jin (2010) approach.
Three of the top most significant genes in this analysis were CHRNA5, MYH10,
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and CLPTM1L, and they each have been independently found to be associated with lung
cancer in previous studies (Spitz et al., 2008; Zienolddiny et al., 2009; Wang et al., 2012).
For the CHRNA5, MYH10, and CLPTM1L genes, the higher criticism p-values are 6·37e-
4, 6·42e-4, and 1·29e-2; the sequence kernel association test p-values are 8·19e-4, 0·41, and
1·54e-5; and the likelihood ratio test p-values are 4·92e-3, 1·96e-3, and 7·05e-4, respec-
tively.
As observed in the power simulations of Section 3, the higher criticism test and
the sequence kernel association test complement each other for these most significant
genes. In order to correct for multiple comparisons, the higher criticism can be used
for signal identification in a hierarchical fashion on the 14396 p-values (Donoho and Jin,
2008) A threshold is set at the point where the test statistics attain the supremum for the
higher criticism and all genes with test statistics more extreme than that threshold are
declared to be disease-associated. This procedure controls for the false non-discovery
rate (Ahdesma¨ki et al., 2010). In our case this procedure selected the four most significant
genes.
As a clear example of why the asymptotic distribution of the higher criticism can
be wildly inaccurate for finite d settings, the asymptotic p-values for CHRNA5, MYH10,
and CLPTM1L are 5·97e-72, 3·83e-64, and 3·27e-12, respectively. These inaccuracies are
amplified in the tails of the distribution which is why the asymptotic p-values differ by
so many orders of magnitude from the exact p-values obtained from Theorem 2.
2.6 Discussion
The proposed analytic method for calculating the p-value of the higher criticism
is exact for any arbitrary finite d for normally distributed test statistics. It is computa-
tionally fast for the common non-large d settings encountered in gene-level analysis in
genome-wide association studies. For non-normally distributed outcomes, such as bi-
nary outcomes in case-control studies, accuracy of the proposed calculations depends on
the accuracy of the normality approximation of individual marginal test statistics. For
large sample sizes, which is often the case in genome-wide association studies, the nor-
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mality assumption of individual test statistics holds quite well and the proposed p-value
calculations for an arbitrary d have high accuracy.
While the vast majority of genes in the genome will have only dozens of genetic
variants, there may be a very few large genes with d being in the thousands. For these
large genes, simulating the null distribution could be less of a computational burden than
the analytic p-value calculation given by Theorem 2. Hence a mixture of both techniques
could lead to a faster overall analysis of genome-wide association data. For example,
Theorem 2 could be used to calculate p-values unless the gene has d > 500 in which case
simulation of the null distribution could be used to obtain the p-value. In the presence of
correlation, the decorrelation transformation (Hall and Jin, 2010) could dampen the non-
null signals when the correlation between some of the marginal test statistics is moderate
or strong. It would be of future interest to develop an alternative higher criticism method
to account for the correlation more effectively to improve the test power.
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3.1 Introduction
With the abundance of genome-wide association studies (GWAS) and with the in-
crease in large-scale sequencing studies, so too must there be development of methodol-
ogy capable of testing complex traits for genetic associations. Initial analysis of GWAS
data has shown to be insufficient in explaining much of the heritability of complex non-
mendelian traits, suggesting that there may not be enough power to simply test single
nucleotide polymorphisms (SNPs) for marginal associations (Manolio et al., 2009). Due
to single SNP analysis being underpowered, particularly for low frequency SNPs, region-
based analyses have become more popular in genetic association studies (Li and Leal,
2008). Genes, gene networks, and pathways are examples of SNP-sets that have sparse
subsets of SNPs that can contribute to disease risk. Methodology that does not require
strong marginal SNP effects but is capable of aggregating these small and sparse SNP
effects together into a detectable signal is needed to help find the causes of the missing
heritability.
Hunter et al. (2007) analyzed the Cancer Genetic Markers of Susceptibility (CGEM)
GWAS breast cancer data, a case-control study with post-menopausal women of Euro-
pean ancestry, and looked at the effects of individual SNPs across the genome. In an
effort to gain more power by looking at SNP-sets instead of individual SNPs, Wu et al.
(2010) scanned the genome at the gene level and found the FGFR2 region to be signif-
icantly associated with breast cancer. Though the region contained 35 SNPs, the signal
was sparse with only four of the SNPs showed any association with disease. Marginally,
none of those four SNPs were at genome-wide significance levels due to the large mul-
tiple testing problem. However, when the signal from all SNPs in the region are were
treated as a unit, then the association became more significant. Due to their close proxim-
ity, it is common for SNPs within the same gene to be correlated, also known as being in
linkage disequilibrium (LD). This demonstrates the importance of having methodology
for testing SNP-sets that is powerful when the signal is sparse while accounting for the
LD between SNPs.
The higher criticism (HC) is a SNP-set test that combines information over all the
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marginal test statistics (Donoho and Jin, 2004) and is ideal for detecting a sparse few
disease-associated SNPs out of a much larger pool of unassociated SNPs than compara-
ble methods (Arias-Castro et al., 2011). While originally designed for high dimensional
settings with independence between SNPs, an adaptation to the higher criticism, the
innovated higher criticism (iHC), first transforms the test statistics to independent test
statistics using the Cholesky decomposition of the correlation matrix and then applys the
higher criticism after the transformation (Hall and Jin, 2010). This transformation can be
unstable when SNPs are in high LD. Our numerical results also suggest that the HC based
on the transformed test statistics is subject to considerable loss of power in the presence of
correlation among the SNPs. Additionally, as SNP-sets often are not large and these im-
plementations of the higher criticism give only asymptotic results, they cannot be directly
applied to most SNP-sets without the use of simulation.
Several methods have been proposed for SNP-set testing, such as MinP and
variance-component tests. MinP calculates the marginal test statistic for each SNP in
the SNP-set and then uses the maximum (or most extreme) marginal test statistics as the
representative test statistic while adjusting for correlation within the SNP-set (Conneely
and Boehnke, 2007; Moskvina and Schmidt, 2008; Cheverud, 2001; Nyholt, 2004; Kimmel
and Shamir, 2006; Han et al., 2009; Zhang and Liu, 2011). MinP has low power when a
sparse set of individual SNPs don’t have strong signals and instead combine together to
form a strong signal. Variance-component tests such as the Sequence Kernel Association
Test (SKAT) (Wu et al., 2011b) offer an alternative to MinP for detecting SNP-set associa-
tions by combining all SNP information over the SNP-set (Liu et al., 2007, 2008; Lin, 1997;
Neale et al., 2011). However if the signal in the region is sparse, then SKAT can have low
power due to giving equal weight to noncausal SNPs in the region, which can cover up
the signal with noise. As a result, the limitation for both MinP and SKAT is that they
both may not be as effective as the higher criticism in accounting for sparse alternatives
(Arias-Castro et al., 2011).
In this paper we present the generalized higher criticism (GHC) test statistic that is
suitable for SNP-sets containing a finite set of correlated markers that does not require any
transformation of the original test statistics. In contrast to the original higher criticism, the
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GHC is flexible to any correlation structure and its analytic p-values can be obtained in an
accurate and computationally efficient manner. The power of GHC relative to iHC, SKAT,
and MinP is compared over extensive simulations using SNP-sets with varied correlation
structures. While MinP and SKAT are sensitive to sparsity, the robust power of GHC
is demonstrated through simulation over regions with varying degrees of sparsity. The
robust nature of GHC is also seen when these methods are compared in their analysis of
the CGEM GWAS breast cancer data.
The remainder of the paper is organized as follows. In Section 2, we introduce
the SNP-set generalized linear model. In Section 3, we present the asymptotic properties
of the HC as well as the problems it has accounting for correlation in SNP-sets. In Sec-
tion 4, we describe the procedure for obtaining p-values for the GHC. In Section 5, the
asymptotic detection boundary for GHC is established. In Section 6, we evaluate the per-
formance of the GHC relative to comparable methods using simulation. In Section 7, the
GHC and competing methods are used to analyze the CGEM breast cancer GWAS data.
Finally, we conclude with discussions in Section 8.
3.2 Generalized linear model and marginal SNP score test
statistics
We consider a sample of N individuals genotyped over a region with p observed
SNPs in a SNP-set. Possible SNP-sets include genes, gene networks, or genetic pathways.
Individuals have phenotypes Y = [Y1, ..., YN ]T . The N by p genotype matrix G is con-
structed such that Gi = [Gi1, ..., Gip]T with GTi as the ith row vector of G containing the
genotypes for the ith individual. The N by q matrix X contains non-genetic covariate
information for the sample with Xi = [Xi1, ..., Xiq]T and XTi being the ith row vector of
X containing the covariate values for the ith individual. We suppose that conditional
on (Xi,Gi), Yi follows a distribution in the exponential family (MacCullagh and Nelder,
1989) f(Yi) = exp{(Yiθi−b(θi))/ai(φ)+c(Yi, φ)}, where f(Yi) is the conditional distribution
of Yi|(Xi,Gi), a(·), b(·), and c(·) are known functions, θi is the canonical parameter, and
φ is the dispersion parameter. In order to construct a marginal test between the jth SNP
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and Y we model µi = E(Yi|Gi,Xi) = b′(θi) as using the GLM (MacCullagh and Nelder,
1989)
g(µi) = X
T
i α+G
T
i β (3.1)
where g(·) is a link function and (α,β) are the regression coefficients. For simplicity,
we here restrict to the canonical link. The variance of Yi is V ar(Yi) = aiφv(µi), where
v(µi) = aiφb
′′(θi) is a variance function. We are interested in testing for the overall effect
of the SNP setGi, which corresponds to the global null H0 : β = 0.
LettingW = diag{a1φv(µˆ01), ..., anφv(µˆ0n)} andP = W −WX(XTWX)−1XTW ,
the marginal score test statistic for βj under the global null is
Zj =
GTj (Y − µˆ0)√
GTj PGj
(3.2)
where µˆ0 = µ(Xαˆ), and αˆ is the MLE of α under the null model of g(µi) = XTi α. These
individual SNP test statistics are asymptotically jointly distributed as Z ∼ MVN(0,Σ)
where we estimate Cov(Zj, Zk) = Σjk by
Σˆjk =
GTj PGk√
GTj PGj
√
GTkPGk
While the Z are correlated we define the uncorrelated transformed test statistics
Z∗ to be
Z∗ = U−1Z ∼MVN(0, Ip)
where UUT = Σˆ is the Cholesky decomposition.
3.3 The higher criticism
The higher criticism tests H0 : β = 0 from model (3.1) against the alternative that
a sparse set of the βj are nonzero. An idea proposed first in passing by Tukey, the higher
criticism was developed by Donoho and Jin (2004) for summary statistics in the setting
where the under the alternative the marginal test statistics come from a mixture of normal
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random variables, as well as by Arias-Castro et al. (2011) in the regression setting. Because
the Z are correlated, Hall and Jin (2010) proposed a higher criticism test based on the
transformed Z∗. To do so let
S∗(t) =
p∑
j=1
1{|Z∗j |≥t}
Note that under H0, S∗(t) ∼ Binomial(p, 2Φ¯(t)) where Φ¯(t) = 1 − Φ(t) is the survival
function of the normal distribution. The innovated higher criticism test statistic is defined
as
iHC = supt≥t0
{
S∗(t)− 2pΦ¯(t)√
2pΦ¯(t)(1− 2Φ¯(t))
}
for some t0 ≥ 0. This test rejects H0 for large values of iHC. If we allow p → ∞ the
higher criticism has been shown to be powerful for high sparsity situations (i.e. when the
number of βj 6= 0 are less than √p) (Donoho and Jin, 2004; Hall and Jin, 2010). For very
large p, iHC can be viewed as the supremum of a normalized empirical process which
converges asymptotically to a Gumbel distribution at a very slow rate of O{(logp)−1/2}
(Jaeschke, 1979). With such a slow rate of convergence, the size of the test is drastically
incorrect when using the asymptotic distribution to calculate P-values for p as large as a
million (Barnett and Lin, 2013). Around 92% of genes in GWAS have p < 50, and with
most functional networks and pathways containing a few hundred genes, the size of SNP-
sets in both gene-level and pathway-level analyses are generally not large enough for the
asymptotic distribution of the iHC to be of any practical use.
For finite p we must take a different analytic approach to find the distribution of
the iHC statistic. An exact P-value calculation for iHC that does not rely on asymptotics
has been developed for this situation (Barnett and Lin, 2013). This P-value calculation
is an exact and computationally efficient method for all finite p, and therefore ideal for
testing SNP-sets in genetic association studies. However, there are drawbacks due to
having to first transform the marginal test statistics from Z into Z∗. In the presence of
even moderately small correlation, there can be a significant loss of power due to the
noise diluting the sparse signals after being mixed in the transformation. For example,
alleles in the FGFR2 gene have been linked to breast cancer risk (Hunter et al., 2007).
The CGEM breast cancer data has 35 SNPs in the gene, four of which have marginal
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test statistics greater than 4.3 in absolute value indicating a strong association between
FGFR2 and breast cancer incidence. However, after transforming these test statistics to
become Z∗, none of the transformed statistics exceed 2.6 in absolute value (Figure 3.1).
These transformed test statistics are so attenuated towards the null that it can lead to
a significant loss in power. This motivates our generalization of the higher criticism to
accomodate the use of the original untransformed correlated test statistics Z in order to
avoid this loss of power.
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Figure 3.1: The marginal test statistics for 35 SNPs from the FGFR2 gene, each with
MAF > 0.05, from the CGEM genetic association study of breast cancer are plotted. The
original test statistics Z are in the top histogram, while the transformed test statistics
Z∗ = U−1Z are in the bottom histogram.
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3.4 The generalized higher criticism
If the LD structure in a gene or SNP-set is even moderately weak, it is likely that
transforming Z by U−1 can result in the transformed test statistics Z∗ being underpow-
ered. In addition, for stronger LD, the matrix inverse operation ofU−1 can be quite unsta-
ble. In order to avoid this problematic transformation we propose the generalized higher
criticism test statistic based on the original Z.
3.4.1 Definition of the generalized higher criticism
We define S(t) as
S(t) =
p∑
j=1
1{|Zj |≥t}.
For general Σ 6= Ip, S(t) is no longer binomial. The correlation, whether positive or
negative, increases the variability of S(t). To see this we estimate Cov(S(tj), S(tk)) using
the sample correlation Σˆ and the following identity:
Theorem 3. Let rn = 2
p(1−p)
∑
1≤k<l≤p(Σkl)
n and let Hi(t) be the Hermite polynomials:
H0(t) = 1,H1(t) = t,H2(t) = t2 − 1 and so on. Then
Cov
(
S(tk), S(tj)
)
= p[2Φ¯(max{tj, tk})− 4Φ¯(tj)Φ¯(tk)]
+4p(p− 1)φ(tj)φ(tk)
∞∑
i=1
H2i−1(tj)H2i−1(tk)r2i
(2i)!
The proof of Theorem 3 is left to Appendix C.1. Using Theorem 3 with Σˆ instead
of Σ we obtain estimates of V ar(S(t)). Though Theorem 3 involves an infinite sum, the
terms tend to zero so rapidly that in practice we suggest that only the first 8 terms are
necessary for estimating the covariance with great accuracy. With these estimates we
define the generalized higher criticism test statistic to be:
GHC = sup
t≥t0
S(t)− p · 2Φ¯(t)√
V̂ ar(S(t))
 (3.3)
For simplicity we will assume t0 = 0. In the independent case when Σˆ = Ip the GHC
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statistic reduces toHC. The stronger the correlation structure, the larger the denominator
(3.3) becomes. However the GHC numerator tends to be larger than the HC numerator
due to the transformed Z∗ being attenuated towards the null.
The asymptotic properties of GHC are highly dependent on the correlation Σ. If
Σjk = 0 for |j − k| > b for some fixed bandwidth b, then as N, p→∞Hoeffding and Rob-
bins (1948) show that (S(t)− p · 2Φ¯(t))(V̂ ar(S(t)))−1/2 tends toward the standard normal
distribution with their central limit theorem for dependent random variables. By taking
the supremum over all t ≥ t0 we are then faced with a gaussian process, and the same
convergence issues seen with the distribution of iHC are present for GHC as well. In or-
der to obtain accurateGHC P-values, we propose in the next section a P-value calculation
for GHC in finite p settings that does not rely on asymptotics.
3.4.2 Calculation of the generalized higher criticism P-value
For a given observed GHC statistic, h, we show in Appendix A.2 that the corre-
sponding P-value is
pr (GHC ≥ h) = 1−
p∏
k=1
p−k∑
a=0
qk,a (3.4)
where for k > 1
qk,a =
p−k+1∑
m=0
pr
(
S(tk) = a
∣∣∣∣S(tk−1) = m, k−2⋂
l=1
{S(tl) ≤ p− l}
)
qk−1,m∑p−k+1
l=0 qk−1,l
,
for k = 1, q1,a = pr(S(t1) = a), and tk is solved for in the equation
h
√
V̂ ar(S(tk)) + 2pΦ¯(tk) = p− k + 1 (3.5)
for each k ∈ {1, ..., p}.
When the test statistics are independent Σ = Ip, then S(t) is the sum of indepen-
dent indicator variables and the distribution of S(tk) conditional on S(tk−1) = m and
∩k−2l=1 {S(tl) ≤ p − l} is binomial with m events and probability of success Φ¯(tk)/Φ¯(tk−1).
When calculating the P-value for GHC for general Σ, S(t) is not binomially distributed.
Instead, in order to account for the additional variability the distribution of S(tk) con-
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ditional on S(tk−1) = m and ∩k−2l=1 {S(tl) ≤ p − l} is approximated with beta-binomial
distribution.
The condition distribution of S(tk) is approximated by
pr
(
S(tk) = a
∣∣∣∣S(tk−1) = m, k−2⋂
l=1
{S(tl) ≤ p− l}
)
≈ pr (S(tk) = a | S(tk−1) = m) .
This approximation is an equality if the marginal test statistics are independent due to
the markov property of empirical processes (Gaenssler, 1983). The variance of S(tk) con-
ditional on S(tk−1) = m is obtained by conditioning on which of the m different |Zj| are
greater than tk−1. The expectation is m · Φ¯(tk)/Φ¯(tk−1) just like in the independent case.
Using these first two moments, the parameters of the beta-binomial distribution (α and
β) are solved for numerically using moment matching in the equations
m
Φ¯(tk)
Φ¯(tk−1)
=
mα
α + β
2
(
m
2
)(
p
2
) ∑
j<l
pr(|Zj|, |Zl| > tk)
pr(|Zj|, |Zl| > tk−1) +m
Φ¯(tk)
Φ¯(tk−1)
−
(
m
Φ¯(tk)
Φ¯(tk−1)
)2
=
mαβ(α + β +m)
(α + β)2(α + β + 1)
where pr(|Zj|, |Zl| > tk) can be obtained as in Schwartzman and Lin (2011) (see Appendix
A.1)). The unconditional distribution of S(tk) can be obtained in the same way by substi-
tuting tk−1 = 0 and m = p.
3.5 The detection boundary of GHC
Though the GHC test is designed for testing SNP-sets where p is often not large,
its asymptotic properties can still help provide some insight into its performance. One
way to analyze the validity of a testing procedure in an asymptotic sense in multivariate
problems is to study the minimax decision errors. Although minimax considerations are
often only of theoretical interest and involves a pessimistic view towards error measure-
ments, it provides an optimality criteria in multivariate problems where most powerful
tests, even in the class of unbiased tests, do not exist. In the context of Gaussian linear
regression, the minimax detection boundary of testing global null against sparse alterna-
tives has been extensively studied Arias-Castro et al. (2011); Ingster et al. (2010). Extend-
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ing these results to the generalized linear model framework is a more difficult problem
(Mukherjee et al., 2013) and so we will consider the case where µ = Gβ. We will show
that the GHC test attains the same detection boundaries obtained in (Arias-Castro et al.,
2011; Ingster et al., 2010). In the following, we first state our problem and asymptotic
framework properly and then discuss optimality properties of GHC.
Let M(β) =
∑p
j=1 I(βj 6= 0) and let Rpk = {β ∈ Rp : M(β) ≥ k}. For some A > 0,
we are interested in testing the global null hypothesis
H0 : β = 0 vs H1 : β ∈ ΘAk = {β ∈
⋃
k′≥k
Rp
k′ : min{|βj| : βj 6= 0} ≥ A}. (3.6)
Set k = p1−α with α ∈ (0, 1]. We note that this types of alternatives has been considered
by Arias-Castro et al. (2011), referred to as the “Sparse Fixed Effects Model” or SFEM.
We study the asymptotic properties of our testing problem in the high-dimensional
regime, i.e., with p → ∞ and n = n(p) → ∞. To introduce our minimax formulation of
the problem, let for any test T the worst case risk be
R(T) := P0(T = 1) + max
β∈H1
[Pβ(T = 0)] . (3.7)
where a test is a measurable function of the data taking values in {0, 1}. Adopting termi-
nology from Arias-Castro et al. (2011), we say that a sequence of tests {Tn,p} is asymp-
totically powerful if limp→∞R(Tp) = 0 and we say that it is asymptotically powerless if
lim infp→∞R(T,p) = 1. The detection boundary of the testing problem (3.6) is the demarca-
tion of signal strength A which determines whether all tests are asymptotically powerless
(we call this Lower Bound of the problem) or there exists some test which is asymptoti-
cally powerful (we call this the Upper Bound of the problem).
Arias-Castro et al. (2011) demonstrate that under certain low-correlation conditions
on Σ, the higher criticism is optimally asymptotically powerful. For α > 1
2
, Arias-Castro
et al. (2011) demonstrate the detection boundary
ρ∗(α) =
{
α− 1/2 if 1/2 < α < 3/4
(1−√1− α)2 if 3/4 ≤ α < 1 (3.8)
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is such that all tests are asymptotically powerless if A =
√
2rlogp with r < ρ∗(α). In
Theorem 3 of Arias-Castro et al. (2011) they show that a test based on
HC∗(s) = max
t∈[s,
√
5logp∩N]
{
S(t)− 2pΦ¯(t)√
2pΦ¯(t)(1− 2Φ¯(t))
}
is asymptotically powerful everywhere above the detection boundary for any given α and
r > ρ∗(α) when s =
√
2 min(1, 4ρ∗(α))logp and when the correlation structure is not too
strong. More formally, this holds under the following two conditions on Σ:
(i) Strong correlation condition: |Σjk| < 1− (logp)−1 for every j 6= k
(ii) Weak correlation condition: For all j, |{k : |Σjk| > γ}| ≤ ∆
where ∆ = O(p), γ2p1−α(logp)3 → 0, and γ3 = O(p+5α−4) for all  > 0. The strong
correlation condition does not allow any pairwise correlations to be too large, while the
weak correlation condition restricts the number of pairwise correlation much different
from zero that each SNP can have. This correlation framework fits well into the genetic
context, where regions with large p will tend to have an upper limit on the number of
pairwise correlations far from zero for each SNP due to the fact that LD tends to decrease
as the distance between SNPs increases.
The difference between HC∗(s) and GHC is that HC∗(s) assumes S(t) to be bi-
nomially distributed and normalizes by the binomial variance even in the presence of
correlation whereas GHC normalizes by the correct variance term that takes correlation
into account. We will show that, despite this difference, GHC is asymptotically powerful
in the same regions as HC∗(s). Though GHC was defined in (3.3) to take the supremum
over t > t0 for some fixed t0, this only makes sense in the finite p setting. Asymptotically,
we will instead take the supremum over [s,
√
5logp] ∩ N as done with HC∗(s).
Theorem 4. Under the conditions (i) and (ii) on Σ then the test based on GHC with the
supremum taken over [
√
2 min(1, 4ρ∗(α))logp,
√
5logp] ∩ N is asymptotically powerful
against alternatives defined by sparsity p1−α′ , α′ ≥ α > 1/2, A = √2rlogp, and r > ρ∗(α′)
The proof of Theorem 4 is left to Appendix C.2. The implications of Theorem 4
are that when correlation between SNPs is fairly weak, then GHC has the same asymp-
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totic performance as HC. It also suggests that the GHC test can have greater power than
comparable methods when there are a sparse few SNPs associated with disease in large p
settings. However it is important to note that this large p performance will not necessar-
ily translate to finite p situations with stronger correlation structures that are frequently
encountered in genetic association studies. Next, we evaluate this finite p performance
through simulation.
3.6 Simulation studies
3.6.1 Type I error of GHC
In order to determine the accuracy of the P-value calculation for the GHC, the Type
I error of the method is estimated through simulation. To mimic the CGEM breast cancer
data, a subset of 35 common HapMap SNPs with minor allele frequency (MAF) greater
than 0.05 in the FGFR2 gene were simulated using the LD structure from the CEU pop-
ulation in the HapMap project. Because the Type I error is possibly dependent on the
strength of the LD in the region being tested, two subsets of FGFR2 are separately con-
sidered. A subset of 8 SNPs in high LD with each other and a different subset of 8 SNPS
in low LD with each other are used to estimate the Type I error in high and low LD cases,
respectively.
For each subset, the 8 SNPs are treated as a SNP-set and 1000 cases and 1000
controls are generated from logistic regression model (3.1) with β = 0, Xi = 1, and
α = −0.5.The GHC P-value in (3.4) is calculated for each simulated dataset and this is
repeated 50 million times in order to have Type I error estimates for genome-wide signifi-
cance levels as small as 10−6. To see that the size of the GHC is correct in the more general
case beyond FGFR2, we also simulated Type I error in the same way except by using ran-
domly selected genes from chromosome 5 for each iteration. In each setting, Type I error
is accurate at all significance levels, though slightly conservative for stronger correlation
structures (Table 3.1).
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GHC Type I error simulations
Significance level Strong LD(FGFR2 subset)
Weak LD
(FGFR2 subset) Random chr5 genes
α = 5.0 · 10−2 4.62 · 10−2 4.91 · 10−2 4.64 · 10−2
α = 1.0 · 10−2 9.59 · 10−3 1.04 · 10−2 9.53 · 10−3
α = 1.0 · 10−3 9.63 · 10−4 1.08 · 10−3 9.80 · 10−4
α = 1.0 · 10−4 9.51 · 10−5 1.00 · 10−4 9.63 · 10−5
α = 1.0 · 10−5 9.70 · 10−6 9.50 · 10−6 8.05 · 10−6
α = 1.0 · 10−6 8.60 · 10−7 7.00 · 10−7 8.63 · 10−7
Table 3.1: Type I error is estimated in each setting with 50 million simulations. The strong
LD setting is based on a subset of 8 FGFR2 HapMap SNPs that are in high LD with one
another. The weak LD setting is based on a subset of 8 FGFR2 HapMap SNPs that are in
weak LD with one another.
3.6.2 Power comparisons for different LD and sparsity settings
The power of GHC, iHC, SKAT, and MinP is compared in situations where the
sparsity and LD structure of the SNP-set vary. SKAT is a variance component score test
that rejects the null hypothesis of β = 0 for large values of the quadratic form (Y −
µˆ)′GRτG′(Y − µˆ) where Rτ = (1− τ)I + τ11′, µˆ is the expectation of Y under the null
hypothesis, and τ is selected to minimize the P-value. The package SKAT in the statistical
computing software, R, is used to calculate the P-values. The MinP test statistic is the
largest (in absolute value) marginal test statistic Zj from (3.2) taken over all the SNPs
in the region. For each setting in the power simulations, the MinP test statistic is also
simulated 5000 times assuming the null distribution so that P-values can be obtained by
comparing to the null distribution.
Genotype matrices were generated with N = 2000 (1000 cases and 1000 controls)
and p = 40 with each SNP having MAF = 0.30. The genotype matrices are generated
such that all causal variants have pairwise correlation ρ1 with each other, all non-causal
variants have pairwise correlation ρ3 with each other, and each causal variant has pair-
wise correlation of ρ2 with each non-causal variant. Power is simulated for ρ1 = 0, 0.4 ,
ρ3 = 0, 0.4 , and for ρ2 for all non-negative multiples of 0.01 that result in positive definite
Σ. Two sparsity settings are considered, 2(5%) causal variants and 4(10%) causal variants,
and in each case the causal SNPs are given an effect size of β = 0.18 and β = 0.10, respec-
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Figure 3.2: Genotypes are simulated with no correlation within the causal variants (ρ1 =
0). Starting with ρ2 = 0, power is estimated from 500 simulations for each possible ρ2 > 0
that is a multiple of 0.01. There is a limit on how large ρ2 can be relative to ρ1 and ρ3 so
that the correlation matrix remains positive definite, and for this reason the range of ρ2
values that power is estimated for varies with ρ1 and ρ3.
tively. Noncausal SNPs have β = 0. The dichotomous traits are generated according
to
logit(P (Yi = 1|Xi,Gi)) = −1.8 + 0.05Xi1 + 0.01Xi2 +
p∑
j=1
βjGij (3.9)
where Xi1 and Xi2 are independent standard normal random variables. Cases and con-
trols are generated in this fashion until 1000 cases and 1000 controls are obtained. In each
sparsity and correlation setting, 500 simulations are performed and power is reported
at the 0.01 significance level. The results are displayed for ρ1 = 0 in Figure 3.2 and for
ρ1 = 0.4 in Figure 3.3.
In order to compare power in a more realistic setting with more complex LD struc-
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Figure 3.3: Genotypes are simulated with 0.4 correlation within the causal variants (ρ1 =
0.4). Starting with ρ2 = 0, power is estimated from 500 simulations for each possible
ρ2 > 0 that is a multiple of 0.01. There is a limit on how large ρ2 can be relative to ρ1 and
ρ3 so that the correlation matrix remains positive definite, and for this reason the range of
ρ2 values that power is estimated for varies with ρ1 and ρ3.
tures, power simulations are repeated on randomly selected genes from chromosome 5
using the 1000 cases and 1000 controls generated in the same fashion as (3.9). Genotype
data is generated from common HapMap SNPs using the LD structure from the CEU
population in the HapMap project. Causal SNPs are selected at random from within each
gene and the two sparsity settings considered are 1 causal variant and 2 causal variants,
with each causal SNP given an effect size of β = 0.30 and β = 0.18, respectively. For
each of the 839 genes in chromosome 5 containing more than 1 SNP, 100 simulations are
used to estimate the power. Because the power will depend on the size of each gene, p,
as well as the minor allele frequency of the causal SNPs, Figure 3.4 shows a smoothed
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power curve in order to represent the power averaged over all genes. In this case, ρ2 is
the median pairwise correlation between causal and non-causal variants. These results
mirror the results from the artificially generated genotype matrices in Figures 3.2 and 3.3
with the only difference being that power for all methods is lower for smaller ρ2 in Figure
3.4 because in real data lower correlation is often an artifact of low allele frequency which
in turn leads to low power. This trend is not present in the artificial genotypes where
allele frequency is fixed for all SNPs regardless of the correlation.
Based on these results, GHC and MinP are more similar in performance to each
other in most settings than they are to either SKAT or iHC. This is not surpising because
they are both tests based on the extreme marginal test statistics while ignoring the less
significant test statistics except for taking correlation of the region into account. On the
other hand, iHC is based on the the extreme transformed marginal test statistics, which
tend to be quite different, and SKAT is a weighted sum of the squares of all the marginal
test statistics. GHC improves in performance relative to MinP when ρ1 increases, ρ2 in-
creases, or sparsity decreases. The iHC test has lower power than GHC in all settings with
correlation present. SKAT improves relative to MinP and GHC as sparsity decreases, but
has very low power when ρ2 is low while ρ3 is large. The reason for this is because in this
situation the non-causal variants dominate the region’s LD structure and because they are
independent of the causal variants, they almost completely mask the sparse signal. GHC
and MinP are robust to this due to their reliance on only the extreme test statistics and
receive only a slight penalty in power when taking the LD into account.
Overall, MinP is ideal when there is only 1 causal variant and no LD in the region,
and diminishes in power relative to other methods as sparsity decreases from there. SKAT
does very well in low sparsity settings, but requires the causal variants to be highly cor-
related with the non-causal variants (ρ2  0) if sparsity is high and non-causal variants
are in LD. In contrast, GHC is is very robust to all correlation structures and all sparsity
levels, and outperforms iHC in the presence of correlation between SNPs in the region.
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Figure 3.4: For each of the 839 genes in chromosome 5, causal SNPs are selected at random
and power is estimated at the α = 0.05 level based on 100 simulations. Additionally,
the median correlation between causal SNPs and noncausal SNPs (ρ2) is recorded. The
smoothed curves to each of these power estimates is displayed.
3.7 Application to the CGEM breast cancer genetic data
The effectiveness of GHC to detect disease-associated genes next to comparable
methods is explored on a breast cancer GWAS data set. A total of 1145 postmenopausal
women of European ancestry with breast cancer and 1142 controls were included in the
CGEM genome-wide association study (Hunter et al., 2007). These women were geno-
typed at 528173 loci using an Illumina HumanHap500 array. The logistic regression
model (3.1) was used while controlling for the covariates: age, post-menopausal hor-
mone usage, and the top three principal components to correct for population stratifica-
tion (Price et al., 2006). Hunter et al. (2007) performed individual SNP analysis. Four
SNPs in the FGFR2 region had marginal P-values less than 1.7 · 10−5 and none of them
were close to genome-wide significance levels. The most significantly associated SNP in
FGFR2 (rs1219648) was validated in further studies. However, as we will see, by grouping
information across multiple SNPs in a gene, the effect of FGFR2 is more significant. Genes
with a 20kb buffer region were used to group SNPs into SNP-sets. GHC, iHC, SKAT, and
MinP were all used to analyze the data for gene-level analysis, and the P-values for all
four methods are displayed in Table 3.2 for genes with the most significant breast cancer
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CGEM breast cancer GWAS gene-level results
Gene p GHC iHC SKAT MinP
FGFR2 35 2.41 · 10−5 1.07 · 10−1 3.56 · 10−5 8.05 · 10−5
TBK1 11 3.47 · 10−4 3.86 · 10−3 5.63 · 10−5 8.39 · 10−4
PTCD3 12 5.77 · 10−5 1.11 · 10−3 1.15 · 10−4 2.18 · 10−4
POLR1A 16 6.90 · 10−5 1.35 · 10−2 3.97 · 10−4 3.10 · 10−4
CNGA3 26 2.37 · 10−4 1.14 · 10−3 1.09 · 10−4 1.12 · 10−3
XPOT 9 5.53 · 10−4 1.76 · 10−2 1.60 · 10−4 9.93 · 10−4
VWA3B 51 6.06 · 10−4 9.39 · 10−2 2.06 · 10−4 1.86 · 10−3
C11orf49 24 2.39 · 10−4 3.49 · 10−3 3.84 · 10−4 3.41 · 10−3
MMRN1 10 4.54 · 10−4 9.35 · 10−3 3.83 · 10−2 2.86 · 10−4
DGKQ 9 3.98 · 10−4 6.45 · 10−3 7.41 · 10−3 2.95 · 10−4
SCARB2 22 5.62 · 10−4 6.80 · 10−2 7.08 · 10−4 4.19 · 10−4
TMEM175 10 5.76 · 10−4 1.11 · 10−2 3.52 · 10−3 4.22 · 10−4
HCN1 36 8.65 · 10−4 8.14 · 10−3 1.85 · 10−2 4.24 · 10−4
AGMAT 5 4.83 · 10−4 3.26 · 10−3 4.62 · 10−4 5.62 · 10−4
NTSR1 32 4.74 · 10−4 7.17 · 10−3 7.13 · 10−3 2.43 · 10−3
Table 3.2: P-values from the CGEM breast cancer GWAS for all four methods are reported.
The list is sorted in increasing order based on the smallest of the four P-values.
associations.
The Q-Q plot based on the GHC gene-level P-values for this GWAS are presented
in Figure 3.5. For the most significant gene, FGFR2, the GHC had the smallest P-value
of 2.41 · 10−5. This P-value should not be directly compared with SNP-level P-values be-
cause there is less of a multiple testing problem (528173 SNPs compared to 14991 genes).
It should also be noted that the iHC P-value for FGFR2 is 0.107 which reflects the atten-
uated marginal test statistics seen in Figure 3.1. The second most significant gene, TBK1,
is closely related to IKBKE, a known breast cancer oncogene (Boehm et al., 2007). For
TBK1, SKAT detected the association with the smallest P-value of 5.63 · 10−5. The third
most significant gene, PTCD3, has previously been identified in a gene network signifi-
cantly associated with breast cancer (Jia et al., 2011). For PTCD3, the GHC had the most
significant P-value of 5.77 · 10−5.
Overall for the most significant genes (ordered by the minimum P-value of all four
methods), MinP and iHC tended to yield less significant P-values than GHC and SKAT.
SKAT and GHC both showed similar strength in detecting these top associations, but
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Figure 3.5: Q-Q plot of GHC P-values for the SNP-set testing of the CGEM breast cancer
GWAS data. SNP-sets were constructed at the gene-level, also including SNPs within
20kb from the border of each gene. SNP-sets with 4 or fewer SNPs were not included in
the analysis leading to total of 14991 SNP-sets evaluated.
SKAT had some very insignificant P-values greater than 0.01 for a few of the top 15 genes
(MMRN1 and HCN1) whereas GHC never had a P-value greater than 8.7 · 10−4. This
difference demonstrates how GHC is more robust than SKAT to the LD in the top genes
and is a safer bet in genome-wide association studies where there is a great variety of LD
structures encountered.
3.8 Discussion
In this paper, the higher criticism, a popular sparse signal detection method orig-
inally designed for high dimensional problems, is generalized to the setting of SNP-set
testing in genetic association studies. Unlike the original HC, our GHC is flexible to SNP-
sets of arbitrary size and LD structure. We propose an analytic method to compute the
p-values of GHC for finite samples that is computationally efficient and requires nei-
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ther simulation nor asymptotics in p to obtain its P-values. This is advantageous when
scanning a large number of genes in GWAS. An implementation of the method is freely
available for use in the R package, GHC. We showed through simulation and analysis of
the CGEM breast cancer GWAS data that the GHC is more robust to varied LD structures
than competing methods. In particular, we show that the GHC is more powerful than
the iHC regardless of the LD structure, and as a result should always be the preferred
method.
As demonstrated by the simulation studies and the analysis of the breast cancer
GWAS data, both GHC and SKAT complement each other well. GHC tends to outperform
SKAT in the high sparsity settings while SKAT outperforms GHC when sparsity is low.
This suggests that an omnibus test that combines the strengths of both GHC and SKAT
could potentially be a powerful alternative in a variety of scenarios.
Though the GHC does not require asymptotics in p, asymptotics in the sample size
N is assumed. The marginal test statistics are assumed to be normally distributed, but
this is a poor assumption if SNPs are rare or if the sample size is small. For GWAS this is
not a problem due to their tendency to have large cohorts and only common SNPs geno-
typed. However, if GHC is to be extended to sequencing studies where SNPs can be rare,
then the normality assumption of the marginal test statistics must be relaxed. Advances
in high-throughput sequencing technology are reshaping the field of genetics research,
with more sequencing studies such as the 1000 Genomes Project and the NHGRI Genome
Sequencing Program. It is of future research interest to extend the GHC to sequencing
studies by using a different marginal test statistic that is robust to rare SNPs.
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Appendix A
Power and null distribution derivations
for CEP-SKAT-O
A.1 Rare causal variants are enriched in phenotypic ex-
tremes
We consider a phenotype of the ith individual to be modeled as
yi = α0 +X
′α+G′iβ + i,
where i ∼ N(0, σ2). Here α0 is an intercept term with α = [α1, α2, ..., αm]′ as the vector of
regression coefficients for the covariates Xi, and β = [β1, β2, ..., βp]′ as the vector of regres-
sion coefficients for the p genetic variants Gi = (Gi1, · · · , Gip)′. First we will calculate the
MAF when sampling extremes where there is a single causal variant and no covariate, i.e.,
p = 1 and m = 0. We will then extend the results to multiple causal variants and derive
an analytic relationship between the MAF of a causal variant using extreme phenotype
sampling to the background population MAF.
Under the single causal variant/no covariate model y = βG+ , we desire to show
that an individual’s probability of having at least one minor allele of the causal variant is
increased when their phenotype is extreme. We assume the additive model, but the re-
sults can be easily extended to the dominant-recessive model. Without loss of generality,
we consider the case where the causal variant has a positive effect on phenotype (β > 0),
and show that for c > 0, Pr(G > 0|y > c) > Pr(G > 0).
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We first write
Pr(G > 0|y > c) = Pr(G > 0)Pr(y > c|G > 0)
Pr(y > c)
.
Hence showing Pr(G > 0|y > c) > Pr(G > 0) is equivalent to showing Pr(y > c|G >
0) > Pr(y > c). We condition on G to achieve the desired result:
Pr(y > c|G > 0)− Pr(y > c) = Pr(y > c|G > 0)− Pr(y > c|G = 0)Pr(G = 0)
−Pr(y > c|G > 0)Pr(G > 0)
= {Pr(y > c|G > 0)− Pr(y > c|G = 0)}Pr(G = 0)
> {Pr(y > c|G = 1)− Pr(y > c|G = 0)}Pr(G = 0)
= {Pr(β +  > c)− Pr( > c)}Pr(G = 0) > 0
Hence the MAF of a causal variant among extreme phenotypes is higher than that in
the population. One can easily see that if G is not a causal variant, i.e., β = 0, then
P (G > 0|y > c) = P (G > 0), i.e., the MAF by sampling extremes is the same as in the
population.
We next calculate the expected MAF of a causal rare variant in the presence of single
or multiple causal variants under extreme phenotype sampling. Specifically, we show
below that the expected MAF of a causal variant in extreme phenotype samples can be
written as a function of the MAFs of the p causal variants in the background population,
the threshold and the regression coefficients β’s. Consider the no-covariate model
y = β1G1 + · · ·+ βpGp + . (A.1)
We are interested in estimating Pr(Gj = g|y > c) for g = 0, 1, and 2. For simplicity, we
assume in our analytic calculations no LD between causal variants which is a plausible
assumption when variants are rare. This assumption gives us:
Pr(G1 = g1, ..., Gp = gp) =
p∏
l=1
Pr(Gl = gl).
Note that each Pr(Gl = gl) can be easily estimated from the data. We model the effect
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size of the jth causal variant as βj = −a · log10(MAFj) for some constant a > 0, i.e., we
assume positive effects.
Write
Pr(Gj = g|y > c) = Pr(y > c|Gj = g)Pr(Gj = g)
Pr(y > c)
, (A.2)
which means we need just compute P (y > c) and P (y > c|Gj = g). This can be done by
conditioning on the remaining causal variants as
Pr(y > c) = Pr(
p∑
l=1
βlGl +  > c)
=
2∑
i1=0
· · ·
2∑
ip=0
Pr
{
p∑
l=1
βlGl +  > c|G1 = g1, ..., Gp = gp
}
Pr(G1 = g1, ..., Gp = gp)
=
2∑
i1=0
· · ·
2∑
gp=0
Pr(
p∑
l=1
βlgl +  > c)
p∏
l=1
P (Gl = gl)
=
2∑
g1=0
· · ·
2∑
gp=0
Φ(
p∑
l=1
βlgl − c)
p∏
l=1
Pr(Gl = gl) (A.3)
Calculations for P (y > c|Gj = g) are identical except for there being no need to condition
on the jth variant:
Pr(y > c|Gj = g) =
2∑
g1=0
· · ·
2∑
gj−1=0
2∑
gj+1=0
· · ·
2∑
gp=0
Φ(aβj +
∑
l 6=j
βlgl − c)
∏
l 6=j
P (Gl = gl) (A.4)
It follows from (A.2) that we can calculate the expected MAF in extreme phenotype sam-
ples as a function of the MAF of the causal variants, the threshold c, and the regression
coefficients βj’s in the phenotype model (A.1) as
Pr(Gj > 1|y > c) = E(Gj|y > c)/2 = 0∗Pr(Gj = 0|y > c)+0.5∗Pr(Gj = 1|y > c)+1∗Pr(Gj = 2|y > c).
One can also use equations (A.2) and (A.4) to easily show that Pr(Gj = g|y > c) >
Pr(Gj = g) if β’s are not equal to 0, i.e., the MAF of a causal variant is higher in extreme
phenotype samples than their population counterpart.
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A.2 Null distribution of Continuous Extreme Phenotype
SKAT
Suppose the true NULL model is
yi = X
′
iα+  (A.5)
where Xi = (xi0, xi1, . . . , xim) is the covariates of ith individual with xi0 = 1, and α =
(α0, . . . , αm)
′ is a vector of regression coefficients of Xi, and  ∼ N(0, σ2). Note that we
use a slightly different notation in which Xi includes the intercept. Suppose we select n
samples with either yi > c1 or yi < c2, and denote the selected yi as y∗i . For notational
simplicity, we use i to indicate the selected individuals. Under the null hypothesis, y∗i
follows a truncated Gaussian distribution with the density function
f(y∗i ) =
1√
2piσ2
exp{−(y∗i −X ′iα)2/2σ2}
Φ(ti2) + 1− Φ(ti1) , (A.6)
where ti1 = (c1 −X ′iα)/σ and ti2 = (c2 −X ′iα))/σ. The first derivative of log likelihood
function is
uj =
∂`
∂αj
=
1
σ2
n∑
i=1
xij(yi −X ′iα+mi),
and the second derivative is
Jik =
∂2`
∂αj∂αk
=
1
σ2
n∑
i=1
xijxik(−1 + vi),
where
mi = σ
φ(ti2)− φ(ti1)
Φ(ti2) + 1− Φ(ti1) , and vi =
ti2φ(ti2)− ti1φ(ti1)
Φ(ti2) + 1− Φ(ti1) +
m2i
σ2
.
Define S = −J , y∗ = (y∗1, . . . , y∗n)′, u = (u0, . . . , um)′, andm = (m1, . . . ,mn)′. By the Fisher
Scoring (or Newton Raphson) procedure, new α is
α∗ = α+ S−1u,
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Type I error estimates for Continuous Extreme Phenotype (CEP-SKAT-O)
α-level 0.05 0.01 1× 10−5 2.5× 10−6 1× 10−6
n=500 0.0471 0.0097 1.66× 10−5 4.22× 10−6 1.70× 10−6
n=1000 0.0480 0.0100 1.48× 10−5 4.70× 10−6 2.19× 10−6
n=2000 0.0497 0.0104 1.70× 10−5 4.75× 10−6 2.21× 10−6
Table A.1: Phenotypes were simulated under the null model (A.5) using two covariates
and added Gaussian noise, but with no genotype effects. Estimates are based on 20 mil-
lion simulated p-values. Adjusted SKAT-O was used to adjust the p-value for small sam-
ple size.
hence S(α∗ − α) = u. Since S = X ′V X/σ2, where V = diag{(1 − vi)} and X =
[X1, . . .Xn]
′,
X ′V X(α∗ −α) = X ′(y∗ −Xα−m).
Now we can treat the Fisher scoring algorithm as a weighted least square problem.
Define a working vector
y˜ = Xα+ V −1(y∗ −Xα−m),
and then α∗ is a weighted least square estimtor of the linear model y˜ = Xα + ˜ with
E(˜) = 0 and V ar(˜) = V −1. Since E(y∗i ) = X ′iα −mi, the SKAT test statistic with linear
weighted kernel is
QS = (y
∗ − µˆ)′GWG′(y∗ − µˆ) = (Y˜ −Xα∗)′V GWG′V (Y˜ −Xα∗)
= Y˜ P0GWG
′P0Y˜ ,
where P0 = V − V X(X ′V X)−1X ′V . From V ar(y˜i) = (1 − vi)σ2, the asymptotic null
distribution of QS is ∑
λvχ
2
v,
where λv is the vth eigenvalue of σˆ2P
1/2
0 GWG
′P 1/20 .
Calculations of QS require fitting the null model (A.5) using extreme phenotypes
y∗i under truncated normal likelihood (A.6). The Newton-Raphson method can be used
to estimate α and σ2.
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A.3 Null distribution of the optimal unified test for contin-
uous extreme phenotype
Suppose
Qρ = (1− ρ)QS + ρQB,
which is the test statistic of the proposed unified test, where QS is the SKAT statistic and
QB is the burden test statistic. The class of test statistics Qρ includes both SKAT (ρ = 0)
and the burden test (ρ = 1) as special cases, and pρ is a p-value computed based on Qρ.
Then, the test statistic of the optimal test is
T = min{pρ1 , . . . , pρb}, 0 = ρ1 < ρ2 < . . . < ρb = 1. (A.7)
Define Z = V −1/2GW , z¯ = (z¯1, . . . , z¯n)′, where z¯i =
∑p
j=1 zij/p, and M = z¯(z¯
′z¯)−1z¯′.
We further let
τ(ρ) = p2ρz¯′z¯ +
1− ρ
z¯′z¯
p∑
j=1
(z¯′z.j)2,
where z.j is the jth column of Z. Following the same argument in Lee et al.(2012), it can
be shown that Qρ is asymptotically equivalent as
(1− ρ)(
m∑
k=1
λ˜kηk + ζ) + τ(ρ)η0, (A.8)
where {λ˜1, . . . λ˜m} are non-zero eigenvalues of Z ′(I −M )Z, ηk(k = 0, . . . ,m) are i.i.d χ21
random variables, and ζ satisfies the following conditions:
E(ζ) = 0, V ar(ζ) = 4trace(Z ′MZZ ′(I −M)Z),
Corr(
m∑
k=1
λkηk, ζ) = 0, and Corr(η0, ζ) = 0.
It shows that the Qρs are mixtures of shared random variables, and the only differences
among different Qρs are the mixing coefficients. From this fact, a p-value of T can be ef-
ficiently computed through one dimensional numerical integration. Details can be found
in Lee et al.(2012) (Lee et al., 2012b).
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A.4 Small Sample Adjustment
It is known that the SKAT family tests can produce conservative results when the
trait is binary and the sample size is small. The same conservative pattern can be ob-
served when we test extreme continuous phenotypes. To resolve this issue, we adopt the
same strategy as that in Lee et al.(2012) (Lee et al., 2012a) in which we adjust asymptotic
null distribution of the test statistics by estimating small sample variance and kurtosis.
To estimate these moments, we generate resampled test statistics using the parametric
bootstrap approach. In particular, B sets of truncated normal random variables are gen-
erated from the model (A.6) with estimated αˆ and σˆ under the null hypothesis, and the
variance and kurtosis ofQS andQB are estimated using resampled phenotype sets. Then,
we apply the same algorithm in Lee et al.(2012) (Lee et al., 2012a).
A.5 Theoretical Power Calculation
Power calculation derivations are available for SKAT and SKAT-O, but adjustments
need to be made to account for extreme phenotype sampling. Derivations for power cal-
culations for continuous extreme phenotype SKAT (CEP-SKAT-O) mirror Lee et al.(2012)
Lee et al. (2012b) in their calculation for continuous phenotypes, but a key distinction in
the treatment of the genotype matrix needs to be made. By sampling from the extremes,
causal variants tend to occur more often in the sample than observed in the population,
and the power calculation should reflect this bias appropriately. In a random sample the
MAF of all sampled variants should be consistent for their respective population MAFs
(note that rate of convergence is slow for rare variants). In an EPS sample, consistency is
not achieved and the likelihood of sampling a genotype must be adjusted accordingly in
the power calculation.
To account for this biased sampling of genotypes, a reduced genotype matrix GR
is used in the calculation of the SKAT statistic. We define GR = BG where B is an n by
n diagonal matrix with jth diagonal equal to
√
P (Variant j exists in the EPS sample). We
can calculate B given the upper and lower cutoffs for sampling extreme phenotypes by
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taking the tail probabilities beyond these cutoffs of the normal distribution with a mean
of the jth entry ofGβ and a variance of 1. The resulting test statistic is:
QS = (y
∗ − µˆR)′GRWρG′R(y∗ − µˆR)
where µˆR is the expected value of the truncated normal y∗ and is a function ofGR. Wρ is
the matrix of weights adjusted by ρ through the matrix Rρ as done in Lee et al.(2012) Lee
et al. (2012b) who also recommend to approximate ρ using the percent of causal variants
and percent of variants with a positive effect on phenotype. The distribution of QS under
the alternative hypothesis can then be approximated by a non-central χ2 distribution. The
distribution of QS under the null hypothesis is approximated in a similar manner except
under the assumption of no variant effects. Power is estimated by the area in the upper
tail of the alternative distribution that lies above the critical value taken from the null
distribution.
Power estimates are obtained by averaging the estimated power over many ran-
domly selected regions of equivalent size (we selected 3kb regions) in order to account
for variability of genotypes by region. In each region a new GR is chosen with individu-
als selected based on their probability of being observed in the phenotypic extremes of the
sample given their genotypes. We compare the theoretical powers and empirical powers
in Figure 1.4 and Figure A.1.
A.6 DHS data analysis sensitivity to different cutoffs
In the Dallas Heart Study, we examine how the p-values for all the EPS methods
are affected by altering the extreme phenotype cutoff, and results are presented in Figure
A.2. DEP-N represents DEP-Burden test in the main manuscript. Note that two addi-
tional burden tests, DEP-W and DEP-C are included. DEP-W uses a weighted count with
beta(1,25) weights while DEP-C is an adaptation of CAST for EPS. We range the cutoffs
from 15% to 30% in 1% increments to capture the sensitivity of the tests to different cut-
offs. From the spikes in each methods p-values over slight changes in this cutoff value,
it is clear that inclusion or exclusion of certain individuals could affect the overall signif-
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Figure A.1: In this setting, 60% of variants were considered causal in a 3kb region. The-
oretical power for optimal continuous extreme phenotype SKAT (CEP-SKAT-O) is com-
pared with the empirical power estimated using 300 simulations for each estimate. Four
settings are considered: sampling 10% and 20% high/low extreme phenotypes; 80%/20%
causal variants have positive/negative effects and 100% causal variants have positive ef-
fects.
icance. It is important to note that because we have a fixed sample size of 3476, smaller
cutoffs lead a smaller sizes through EPS. As an example, a tail cutoff of 15% leads to half
the EPS sample size that we would see with a tail cutoff of 30%. Because significance is
sensitive to sample size, direct comparison between p-values at different cutoffs is not
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Figure A.2: The p-values using six EPS association tests using different extreme cutoffs
are demonstrated. Each of the three genes, ANGPTL3, ANGPTL4, and ANGPTL5 are
tested separately. A test combining all three genes is also included.
appropriate in Figure A.2. This analysis is presented for each of ANGPTL3, ANGPTL4,
and ANGPTL5 being tested for separately as well as a combined analysis across the three
genes.
For the three-gene combined analysis, CEP-SKAT-O gives the smallest p-value than
the other methods when the cutoff of selecting extreme phenotypes is less than 22% and
slightly higher p-values than DEP-SKAT-O when the cutoff is greater than 22%. For
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Analysis of the Dallas Heart Study triglyceride data
n=1389 CEP-SKAT-O DEP-SKAT-O RS-SKAT-O DEP-W DEP-N DEP-C
20% 5.0× 10−5 3.0× 10−5 1.3× 10−2 2.5× 10−4 7.2× 10−5 2.1× 10−3
30% 1.0× 10−3 1.9× 10−3 1.3× 10−2 2.0× 10−3 2.8× 10−3 1.7× 10−2
40% 8.9× 10−3 1.2× 10−2 1.3× 10−2 1.2× 10−2 1.9× 10−2 4.5× 10−2
Table A.2: Analysis results of the Dallas Heart Study (DHS) sequence data using various
test methods and sampling schemes. The DHS sequenced 3,476 subjects. A total 1,389
individuals were selected with highest and lowest 20% logTG levels in each age-gender
spectrum. For sampling with higher cutoffs (30% and 40%), 1389 individuals were ran-
domly sub-sampled among the individuals belongs to larger tails. In these cases, median
p-values are presented in the table from 1000 sampling iterations. Since the sample size
was large, the small sample adjustment was not applied. DEP-N represents DEP-Burden
test in the main manuscript. Two additional burden tests are included: DEP-W uses a
weighted count while DEP-C is an adaptation of CAST for EPS.
ANGPL3 gene, CEP-SKAT-O overall has the smallest p-compared with the other meth-
ods. For ANGPTL4 and ANGPTL5 genes, CEP-SKAT-O has similar p-values to DEP-
SKAT-O. Both outperform the burden tests.
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Figure A.3: Simulated power comparisons between four rare variants association tests
with all causal variants having a positive effect on phenotype. The five tests are ran-
dom sample optimal SKAT (RS-SKAT-O), dichotomized extreme phenotype burden test
(DEP-Burden), continuous extreme phenotype burden test (CEP-Burden), dichotomized
extreme phenotype optimal SKAT (DEP-SKAT-O), and continuous extreme phenotype
optimal SKAT (CEP-SKAT-O). The left panel considers the situation where 10% high/low
extremes are sampled with the three rows corresponding to 20% (0.6% heritability), 40%
(1.2% heritability) and 60% (1.8% heritability) variants in a 3kb region being causal. Three
total sample sizes are considered: n=500, 1000, 2000. The right panel considers the situa-
tion where 25% high/low extremes are sampled. Exonic regions are simulated with effect
sizes for each causal variant equal to β = 1. Power is estimated by the proportion of tests
that detect an association at the α = 10−6 level.
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Appendix B
HC p-value calculation details and
inaccuracy of asymptotic distribution
B.1 Proof of Lemma 1
Proof. Recall c(t|h) = h[2dΦ¯(t){1 − 2Φ¯(t)}]1/2 + 2dΦ¯(t). By letting t → 0, we see that
h ≥ 0 and the p-value in this case is 1. Considering a fixed h > 0, we evaluate the
behavior of c(t|h). This function has several important properties. Firstly, c(0|h) = d,
limt→∞ c(t|h) = 0, and the first derivative is
c′(t|h) = dφ(t)
(
h(4Φ¯(t)− 1)
[2dΦ¯(t){1− 2Φ¯(t)}]1/2 − 2
)
.
Letting tmax = Φ−1[1 − {1 + d(h2 + d)−1}/4], we can see from its derivative that c(t|h)
is an increasing function on 0 < t < tmax, achieves its maximum at tmax, and then is a
decreasing function on tmax < t <∞ approaching 0. This along with c(0|h) = d and c(t|h)
being a continuous function gives the result.
B.2 Proof of Theorem 1
Proof. Firstly, we need only consider t ≥ t1 rather than take the intersection over all t > 0.
This is because for 0 < t < t1, c(t|h) > d, and as S(t) can never exceed d, S(t) must be less
than c(t|h) for every t in this interval with probability 1. Therefore
pr
[⋂
t>0
{S(t) < c(t|h)}
]
= pr
[⋂
t≥t1
{S(t) < c(t|h)}
]
.
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Noting that S(t) an integer-valued non-increasing function of t we have for each k in
1, ..., d that ⋂
tk<t≤tk+1
{S(t) < c(t|h)} = {S(tk) ≤ d− k} .
Using this and breaking the intersection into its partition
⋂
t≥t1
{S(t) < c(t|h)} =
d⋂
k=1
⋂
tk<t≤tk+1
{S(t) < c(t|h)} ,
the results follow.
B.3 Inaccuracy of the asymptotic distribution of the higher
criticism in finite d settings
Asymptotically, one needs only take the supremum over a small subset of t > 0
(Donoho and Jin, 2004). However, in finite d settings it is necessary to take the supremum
over the full t > 0 region. This corresponds to  = 0 and δ = 1, and the asymptotic
convergence to the gumbel distribution is even slower in this case than what is observed
in Fig. B.1. At the α = 0·05 significance level, the Type I error is 0·03 for d = 104 if
calculated using the asymptotic distribution with  = 0·01 and δ = 0·40. This inaccurate
Type I error rate for even very large d demonstrates how this asymptotic result is not
useful for even moderately large d settings. The results are displayed in Figure B.1.
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Figure B.1: Comparison of the asymptotic distribution and the empirical distribution of
the higher criticism as a function of d. The supremum of the higher criticism test statistic
is taken over the range Φ−1(1 − δ/2) < t < Φ−1(1 − /2) where  = 0·01 and δ = 0·40.
Each empirical distribution is constructed using 500 samples of d independent standard
normal random variables.
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Appendix C
Proofs of GHC detection boundary and
p-value calculation
C.1 Proof of Theorem 3
Proof.
Cov
(
p∑
k=1
I{|Zk|>ti},
p∑
k=1
I{|Zk|>tj}
)
= E
(
(
p∑
k=1
I{|Zk|>ti})(
p∑
k=1
I{|Zk|>tj})
)
− E
(
p∑
k=1
I{|Zk|>ti}
)
E
(
p∑
k=1
I{|Zk|>tj}
)
= E
(
p∑
k=1
I{|Zk|>max{ti,tj}} +
∑
k 6=l
I{|Zk|>ti}I{|Zl|>tj}
)
− 4p2Φ¯(ti)Φ¯(tj)
= p[2Φ¯(max{ti, tj})− 4Φ¯(ti)Φ¯(tj)] +
∑
k 6=l
[P (|Zk| > ti, |Zl| > tj)− 4Φ¯(ti)Φ¯(tj)]
So it is sufficient to show that
∑
k 6=l
[P (|Zk| > ti, |Zl| > tj)− 4Φ¯(ti)Φ¯(tj)] = 4p(p− 1)φ(ti)φ(tj)
∞∑
n=1
H2n−1(ti)H2n−1(tj)r2n
(2n)!
Letting rk,l = Cov(Zk, Zl), Schwartzman and Lin (2011) showed that
P (Zk > ti, Zl > tj) = Φ¯(ti)Φ¯(tj) + φ(ti)φ(tj)
∞∑
n=1
rnk,l
n!
Hn−1(ti)Hn−1(tj)
77
Because Zk and Zl are bivariate normal we can rewrite P (|Zk| > ti, |Zl| > tj) as:
P (|Zk| > ti, |Zl| > tj) = 2(Φ¯(ti)− P (Zk > ti, Zl > −tj) + P (Zk > ti, Zl > tj))
Plugging back in yields:
∑
k 6=l
[P (|Zk| > ti, |Zl| > tj)− 4Φ¯(ti)Φ¯(tj)]
=
∑
k 6=l
2φ(ti)φ(tj)
∞∑
n=1
rnk,l
n!
Hn−1(ti)(Hn−1(tj)−Hn−1(−tj))
= 2φ(ti)φ(tj)
∞∑
n=1
Hn−1(ti)(Hn−1(tj)−Hn−1(−tj))
n!
∑
k 6=l
rnk,l
= 4p(p− 1)φ(ti)φ(tj)
∞∑
n=1
H2n−1(ti)H2n−1(tj)r2n
(2n)!
C.2 Proof of the GHC P-value calculation
Proof.
pr (GHC ≥ h) = 1− pr
(⋂
t>0
{
S(t) < h
√
V̂ ar(S(t)) + 2pΦ¯(t)
})
= 1− pr
(
p⋂
k=1
{S(tk) < p− k + 1}
)
where the tk are defined in equation (3.5). We are able to write the intersection over all
t > 0 as an intersection of p events due to the monotone nature of h
√
V̂ ar(S(t)) + 2pΦ¯(t)
combined with the fact that S(t) can only take on the values {0, 1, ..., p}. Applying the
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chain rule of conditioning leads to:
pr (GHC ≥ h) = 1− pr
(
p⋂
k=1
{S(tk) < p− k + 1}
)
= 1−
p∏
k=1
pr
(
S(tk) ≤ p− k
∣∣∣∣ k−1⋂
l=1
{S(tl) ≤ p− l}
)
= 1−
p∏
k=1
p−k∑
a=0
qk,a
C.3 Proof of Theorem 4
Proof. Let σa(t) =
√
V ar(S(t)) and σs(t) =
√
2pΦ¯(t)(1− 2Φ¯(t)), and then let HC(t) =
{S(t)−2pΦ¯(t)}/σs(t) and GHC(t) = {S(t)−2pΦ¯(t)}/σa(t). Noting that GHC(t) is a mean
0 variance 1 random variable,
prH0 (GHC > c) ≤
∑
t∈[s,
√
5logp]∩N
prH0(GHC(t) > c)
≤
∑
t∈[s,
√
5logp]∩N
1/c2 by Chebyshev’s Inequality
=
O(
√
logp)
c2
Hence for c = O(logp) we have that prH0(GHC > c)→ 0. Without loss of generality take
c = logp.
Now we study the behavior of GHC under the alternative. By Arias-Castro et al.
(2011) we have that if maxj |βj| ≥
√
6logp, then
HC(
√
5logp) ≥ p3/4 (C.1)
with probability greater than 1 − o(1/√p). For the rest of the alternatives satisfying A ≤
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maxj |βj| ≤
√
6logp, it suffices to show that there exists a t ∈ [s,√5logp] ∩ N such that
EH1(GHC(t)) logp
and
EH1(GHC(t))√
V arH1(GHC(t))
→∞
Noting that GHC(t) = HC(t) σs(t)
σa(t)
, we have that
EH1(GHC(t))√
V arH1(GHC(t))
=
EH1(HC(t))√
V arH1(HC(t))
In Arias-Castro et al. (2011), proof of Theorem 3, they show that for t =
√
2 min(1, 4γ)logp,
EH1 (HC(t))√
V arH1 (HC(t))
→∞. Hence, for the same t, EH1 (GHC(t))√
V arH1 (GHC(t))
→∞.
We will show that for that same t, EH1(GHC(t)) =
σs(t)
σa(t)
EH1(HC(t))  logp. For
the same t, Arias-Castro et al. (2011) show that EH1(HC(t))  (logp)2
√
∆. This implies
that EH1(GHC(t)) σs(t)σa(t)(logp)2
√
∆.
Arias-Castro et al. (2011) showed that V arH0(HC(t′)) ≤ c′(logp)2∆ for some con-
stant c′ > 0. Combine this inequality with the fact that V arH0(HC(t′)) =
σ2a(t
′)
σ2s(t
′) , and we
have that σs(t)
σa(t)
≤ 1√
c′logp√∆ . Hence,
EH1(GHC(t)) 
1√
c′logp
√
∆
(logp)2
√
∆
= O(logp)
Therefore EH1(GHC(t))  logp as required. Now we evaluate the case where t =√
5logp:
GHC(
√
5logp) = HC(
√
5logp)
σs(
√
5logp)
σa(
√
5logp)
 p3/4 1logp√∆ by equation (C.1)
 logp
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